# https://synthesishealth.co.uk llms-full.txt

## Medical Writing Specialists
# Synthesis

## Medical writing specialists

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27415.55555555555554%27%20height=%27623.3333333333334%27/%3e)![Advanced medical facility building](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F748x1122%2F7f6391e023%2Fbuilding-2.png&w=1080&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27576%27%20height=%27439%27/%3e)![Medical research facility ](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1152x878%2F113e513179%2Fbuildings-1.png&w=1200&q=90)

### From concept to  communication

Published in

- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2789%27%20height=%2756%27/%3e)![European Society of Cardiology Journal](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F178x112%2Fce90803b26%2Fesc-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2778%27%20height=%2743%27/%3e)![Allergy & Asthma Proceedings](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F156x86%2F386ab6e1af%2Fallery-asthma-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27173.5%27%20height=%2730.5%27/%3e)![Musculoskeletal Care Journal Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F347x61%2F69a1079c12%2Fmusculoskeletal-logo.png&w=384&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27167%27%20height=%2743%27/%3e)![Dermatologic Surgery Journal](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F334x86%2F919f8b002c%2Fdermatologic-surgery.png&w=384&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27101%27%20height=%2737%27/%3e)![ISH Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F202x74%2Fd423c91c17%2Fish-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2786.5%27%20height=%2734%27/%3e)![Acta Obstetricia et Gynecologica Scandinavica Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F173x68%2F6e7dd26961%2Faogs-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2744%27%20height=%2743%27/%3e)![Orphanet Journal of Rare Diseases Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F88x86%2F8570e41e86%2Forjd-logo.png&w=96&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27172.5%27%20height=%2730.5%27/%3e)![European Journal of Radiology Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F345x61%2F0f07637905%2Fej-radiology-logo.png&w=384&q=90)

Published in

- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2789%27%20height=%2756%27/%3e)![European Society of Cardiology Journal](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F178x112%2Fce90803b26%2Fesc-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2778%27%20height=%2743%27/%3e)![Allergy & Asthma Proceedings](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F156x86%2F386ab6e1af%2Fallery-asthma-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27173.5%27%20height=%2730.5%27/%3e)![Musculoskeletal Care Journal Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F347x61%2F69a1079c12%2Fmusculoskeletal-logo.png&w=384&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27167%27%20height=%2743%27/%3e)![Dermatologic Surgery Journal](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F334x86%2F919f8b002c%2Fdermatologic-surgery.png&w=384&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27101%27%20height=%2737%27/%3e)![ISH Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F202x74%2Fd423c91c17%2Fish-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2786.5%27%20height=%2734%27/%3e)![Acta Obstetricia et Gynecologica Scandinavica Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F173x68%2F6e7dd26961%2Faogs-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2744%27%20height=%2743%27/%3e)![Orphanet Journal of Rare Diseases Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F88x86%2F8570e41e86%2Forjd-logo.png&w=96&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27172.5%27%20height=%2730.5%27/%3e)![European Journal of Radiology Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F345x61%2F0f07637905%2Fej-radiology-logo.png&w=384&q=90)

## Bespoke content development support

[Learn about our process](https://synthesishealth.co.uk/manuscript-support)

25+ years of experience developing healthcare communications content and publications that confidently reflect the advances in disease diagnostics, prevention and treatment, and the patient experience of illness.

[Learn about our process](https://synthesishealth.co.uk/manuscript-support)

## Raising patient voices for a healthier tomorrow

Transformative healthcare begins with consistent, meaningful patient engagement. It's the cornerstone for developing more effective and beneficial therapies and healthcare experiences.

Our commitment? To amplify the voices of patients, carers and advocates through impactful content and publications.

Discover how we can support your patient engagement and advocacy efforts.

[Learn more](https://synthesishealth.co.uk/patient-engagement)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%276000%27%20height=%274000%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F6000x4000%2Fc288d91468%2Fad-board.jpg&w=3840&q=90)

## We work with a methodology you can trust

- ### Concise


Effective medical writing relies on the ability to communicate complex ideas clearly and succinctly to various audiences. Our team of specialist medical writers excels in merging diverse domain knowledge to create content that is both concise and coherent.

- ### Logical

Our medical writing team excels at organising content in a way that maximises its impact and clarity.

- ### Ethical


Medical writing is underpinned by an ethical and compliant development process. Partnering with us ensures trust and credibility in your content.

- ### Accurate

Accuracy is the cornerstone of impactful medical writing. Our team is equipped with the expertise to provide consistent, high-level scientific accuracy, ensuring that your content is both reliable and valuable.

- ### Reputable

Our commitment to concise, logical, ethical, and accurate medical writing enhances the credibility and reputation of your work. We help you convey complex medical information in a way that resonates with and is respected by your audience.


[Book a call](https://calendly.com/synthesis-sam/synthesis-call)

![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1512x688%2F2d52b4bae7%2Fbuildings-rising.png&w=3840&q=90)

## Write the future ofhealthcare today

[Book a call](https://calendly.com/synthesis-sam/synthesis-call)

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.


## Patient Perspectives in Healthcare
# Embracing patient perspectives: A catalyst for advancing healthcare outcomes

In today’s dynamic healthcare landscape, prioritising patient-centricity is no longer an option but a necessity. With the proliferation of digital resources, patient advocacy groups, and social media platforms facilitating an abundance of health-related conversations and access, the patient population has never had access to so much information. (1)

## The patient-centric approach

At the heart of the patient-centric model lies a collaborative partnership between patients and healthcare stakeholders aimed at elevating patient experiences and driving positive healthcare outcomes. In fact, patient engagement is touted by some as the “holy grail” of healthcare due to its potential to improve patient adherence and satisfaction and drive improved clinical outcomes. (2) Adopting a patient-centric culture, therefore, fortifies a company’s commitment to creating better health outcomes for its consumers.

## A shift in paradigm

Historically, pharmaceutical companies have taken a disease-focused, healthcare provider-led approach to treatment, as opposed to understanding the person with the condition as a whole, resulting in a chasm between the perceptions of patient and physician. (1) Recent years have seen a paradigm shift towards an approach in which a patient’s needs, desires, preferences and experiences are instead placed at the helm of the healthcare process, marking a significant evolution in healthcare strategies. This shift enables the patient to become an active participant, rather than a mere bystander, in their health and wellbeing. (3)

![](https://a.storyblok.com/f/166410/6000x4000/463ec4e383/happy-patient.jpg)

## The impact of patient insights

Patient insights play a crucial role in helping researchers garner a deeper understanding of the effectiveness of treatments and their associated side effects, offer a glimpse into the patient experience and how they interact with the course of treatment and can inform future study design. By prioritising patient insights, pharmaceutical companies can gain an improved understanding of patients' preferences, behaviours, and lived experiences, facilitating the development of therapies that fit into their lives and improve treatment adherence. (4)

So, what are the key benefits of leveraging patient insights to improve the patient experience?

### 1\. Tailored healthcare solutions (5)

Patient insights allow for the personalisation of treatment interventions, considering individual comorbidities, preferences, needs, and circumstances. This, in turn, can lead to the development of more effective, tailored care plans to optimise therapeutic outcomes.

### 2\. Enhanced patient engagement (6)

Patient engagement has a critical influence on healthcare outcomes and is an important predictor of participant retention throughout clinical trials as a central strategy for bolstering patient compliance and treatment adherence. Involving patients in decision-making can promote greater patient engagement, affecting the overall quality of results and clinical efficacy.

### 3\. Promotes treatment adherence (6)

Aside from the impact on patient outcomes, poor adherence comes at a cost to the payer, society, and the pharmaceutical manufacturer. Patient insights play a pivotal role in identifying factors that may impede adherence to treatment protocols. Leveraging patient perspectives to address these issues and better align treatment plans with patients’ lifestyles and preferences can foster greater adherence and health outcomes.

### 4\. Patient-centred innovation (6)

Interacting with patients can help to identify novel challenges and ideas, sparking innovative solutions and services that address unmet needs and improve healthcare experiences. Appreciating and understanding these insights can inform the development of new technologies, services or programs that resonate with patients and meet their needs.

### 5\. Builds trust and loyalty (2)

Actively engaging with patients, listening, and considering their insights allows pharmaceutical companies to foster trust and enhance their reputation in patient communities. This can create positive associations for patients who see their concerns and experiences being acknowledged, helping build loyalty and a lasting patient-provider relationship that extends beyond the prescription.

### 6\. Improved clinical trial design (2,7)

Continuous patient feedback contributes to the design of more efficient, patient-friendly clinical trials, with studies suggesting that patient-centred trials can increase enrolment, retention rates and success over traditional approaches.

### 7\. Increased patient satisfaction (7)

Understanding patient perspectives and taking an approach driven by their insights leads to care plans that better align with expectations, requirements and preferences and promote higher levels of satisfaction.

### 8\. Better quality healthcare services (7)

The patient outlook can help researchers better understand what matters most to them along their healthcare journey. Offering valuable insights into how organisations can enhance the quality of care, incorporating perspectives and aligning systems with patient-centred goals can effect change and improve healthcare services.

As the pharmaceutical industry journeys towards a healthcare landscape in which a patient-centric approach is no longer a choice but an essential, embracing patient insights unlocks a myriad of benefits that universally enhance the patient experience. (7)

* * *

At Synthesis, we're committed to fostering productive partnerships that promote patient-centric approaches, drive impactful changes, and ultimately improve health outcomes. Contact us to learn more about how we support patient engagement and advocacy initiatives.

* * *

References:

1. [https://www2.iconplc.com/article\_patient\_centric](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)

2. [https://within3.com/blog/patient-centric-culture](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)

3. [https://www.ejprarediseases.org/wp-content/uploads/2021/03/SHORT-GUIDE-ON-PATIENT-PARTNERSHIPS-IN-RARE-DISEASE-RESEARCH-PROJECTS.pdf](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)

4. [https://clearstrategy.com/thinking/why-patient-insight-is-critical-to-improve-patient-outcomes/](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)

5. [https://assets.kpmg.com/content/dam/kpmg/pdf/2016/01/healthcare-insights-dec-2015-2.pdf](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)

6. Pushparajah DS. Making Patient Engagement a Reality. _Patient_. 2018;11(1):1-8. doi:10.1007/s40271-017-0264-6

7. [https://florencehc.com/blog-post/what-is-a-patient-centric-approach-in-clinical-trials/](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient Authored Publications
# Empowering voices: The rise of patient-authored publications in healthcare

The tradition of documenting medical knowledge spans ancient folklore and early medicinal practices, evolving into today's evidence-based medicine. Throughout this evolution, publications have served as crucial tools for disseminating medical information. Traditionally, these documents were authored and later peer-reviewed by medical professionals.

However, within this established structure lies an untold narrative: the voice of the patient. Despite the scientific foundation of professionally authored publications, the perspectives and experiences of those directly affected by medical conditions are often overlooked, missing opportunities for more varied and diverse publications.

## From patient to author

Patient authoring is the concept of creating an article or publication that is authored by a patient and published in a peer-reviewed journal. (1) This includes patients publishing their own research and co-authoring with research teams to present data. Recent years have seen an increase in such publications, with a study in 2020 finding that patient-authored articles in the _British Medical Journal_ rose from 31% in 2015 to 49% in 2020. (1)

This trend highlights the growing recognition of the importance of including patient voices in research publications, providing unique perspectives and opportunities for improved understanding among patients and the wider scientific community. However, patients must meet the following criteria for authorship to ensure the credibility and relevance of their contributions:

- They must live with or be affected by the studied disease or condition. (1)

- They must provide unique and valuable input from the patient’s perspective to publication. (1)

- They must meet all the International Committee of Medical Journal Editors criteria to be an author, including substantial contribution, drafting or reviewing the work, and final approval and agreement to be accountable for all aspects of the work. (1)


As the pharmaceutical industry focuses on involving patients in drug development, individuals are increasingly eager to contribute to research. (1) They seek information from peer-reviewed publications and aim to develop authorship skills, collaborating with research teams. Stakeholders, including major funders such as the National Institute of Health Research and the Patient-Centered Outcomes Research Institute, are also recognising the importance of integrating patient perspectives into research efforts. (1)

![](https://a.storyblok.com/f/166410/5760x3840/7fb1fdfd39/diverse-engagement.jpg)

## 4 key benefits of patient authored publications

### 1\. New ideas

Patients' lived experiences and diverse perspectives offer invaluable contributions to research teams, stimulating discussions and fostering innovation. (2) Their unique insights into diseases or conditions can increase understanding and motivation within teams, ultimately enhancing the quality and relevance of research publications.

### 2\. New strategies

By being a patient themselves or associated with patients, a patient author can offer a unique perspective on strategies for patient involvement, accessibility, recruitment, and retention. (2) Their insights can help navigate challenges and provide alternative viewpoints from their lived experiences.

### 3\. Improved relevance

The relevance of the research to its intended population is paramount, and patient authors offer valuable insight to support alignment with the needs of those it impacts. (2) Their contributions can provide honest advice and guidance on research methods and objectives. They can also enhance the clarity and accessibility of research findings by offering unique perspectives on strategies to optimise information dissemination, therefore ensuring it is accessible to all patients. (2)

### 4\. Increased credibility

The presentation of research data is essential to the credibility of study outcomes. Patient-led data presentation can help to inspire trust and confidence that the interpretation reflects current patient priorities. (2) By involving a patient author, researchers gain insights into the language nuances relevant to addressing patient concerns, thereby enhancing the acceptability and resonance of the research findings. (2)

## Absence of a patient voice

While maintaining a strong scientific foundation is essential, excluding patient authors may result in overlooking their invaluable perspectives from lived experience. This could lead to missed opportunities to refine strategies and enhance publication credibility and accessibility. Furthermore, sponsors may forego certain funding opportunities from major funders who prioritise or mandate patient involvement.

Recognising patient authors as a means to develop holistic and representative publications with broader accessibility is essential in navigating an increasingly patient-centric landscape.

* * *

Whether you are looking for more information on patient authoring or ad-hoc or long-term publications support, contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to learn more about how we can work together to maximise the relevance, reach and credibility of your content.

* * *

References:

1. Oliver J, Lobban D, Dormer L, Walker J, Stephens R, Woolley K. Hidden in plain sight? Identifying patient-authored publications. _Res Involv Engagem_. 2022;8(1):12. doi:10.1186/s40900-022-00346-w

2. Arnstein L, Wadsworth AC, Yamamoto BA, et al. Patient involvement in preparing health research peer-reviewed publications or results summaries: a systematic review and evidence-based recommendations. _Res Involv Engagem_. 2020;6:34. doi:10.1186/s40900-020-00190-w

## Medical Manuscript Writing Support
# 6 ways your medical manuscript could benefit from medical writing support

From single-patient case reports to large multi-centre clinical trials, publishing peer-reviewed manuscripts in scientific journals remains the cornerstone of the scientific process, disseminating novel medical knowledge to the wider medical community to improve global clinical practice.

However, while most clinicians and scientists understand the need to publish their research, approximately half of all medical and health-related research goes unpublished. (1) While lack of time to write or submit manuscripts is cited as the main reason for not publishing, two other factors include language barriers, lack of awareness of current reporting guidelines and publication practices, and inadequate medical writing expertise. (2-3) For those who have the time to write, these factors may also result in poorer quality of writing, leading to higher rejection submission rates.

> "
> \[Manuscripts\] are easy to write badly but require skill and knowledge to write well. A quick scan of any journal will quickly (and depressingly!) reveal the sheer number of poor quality manuscripts in circulation - EMWA (4)"

As specialists in writing for the medical field, medical writers are perfectly placed to help overcome these challenges. They can support researchers by combining diverse domain knowledge with a talent for integrating the authors’ expertise, opinions and input into concise and coherent copy.

> "Professional medical writing support promotes and reinforces scientific integrity and reputation"

Professional medical writing support is linked to improvements in:

1. Adherence to the most up-to-date ethical research and publication guidelines (2,5)

2. Publication rates in journals (5)

3. Publication rates in journals that have a higher impact factor (5)

4. Writing quality (5)

5. Content development timelines (5)

6. Speed of acceptance by journals (2)


Professional medical writing support promotes and reinforces scientific integrity and reputation by developing high-quality, accurate, and compliant content for journal submission. As specialists in medical publications and planning, Synthesis employs a unique ‘CLEAR’ methodology. Ensuring manuscripts are concise, logical, ethical, accurate and reputable, we help maximise the strategic impact and industry-wide value of our client’s research.

You can find out more about our CLEAR methodology [here](https://synthesishealth.co.uk/). Or learn how we can work together to maximise the reach and clarity of your content by [contacting us today](https://synthesishealth.co.uk/work-with-us).

* * *

References:

1. Song F, Loke Y, Hooper L. Why are medical and health-related studies not being published? A systematic review of reasons given by investigators. _PLoS One_. 2014;9(10):e110418. doi:10.1371/journal.pone.0110418

2. Sharma S. Professional medical writing support: The need of the day. _Perspect Clin Res_. 2018;9(3):111–112. doi:10.4103/picr.PICR\_47\_18

3. Khadilkar SS. Rejection Blues: Why Do Research Papers Get Rejected? _J Obstet Gynaecol India_. 2018;68(4):239–241. doi:10.1007/s13224-018-1153-1

4. Riley MJ. Medical Communications. _Medical Writing._ 2016;24(4):55–58

5. Evuarherhe O, Gattrell W, White R. et al. Professional medical writing support and the quality, ethics and timeliness of clinical trial reporting: a systematic review. _Res Integr Peer Rev._ 2019;4(14). [https://doi.org/10.1186/s41073-019-0073-](https://doi.org/10.1186/s41073-019-0073-7)


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Diverse Patient Representation
# Identifying representative patients in healthcare: Why – and how – you should communicate a diverse patient voice

At Synthesis, we advocate for placing the patient voice at the core of our healthcare ecosystem. Working with patients allows healthcare industry professionals to understand and learn from their experiences to shape future research efforts to develop healthcare outcomes to meet patients’ ever-changing needs. While patient centricity is becoming a more conventional approach within pharma, ensuring adequate patient representation may not always be prioritised. Historically marginalised groups have been overlooked in medical research. So, if healthcare is to advance on a universal scale, patient engagement demands a deeply inclusive approach.

Here are just a few reasons to consider promoting diversity and representation of patient communities in research and publications:

### **1\. Individual experiences**

Every patient will have their own personal experiences and journey, from waiting for an appointment to the type of treatment they are prescribed. Therefore, each individual will encounter unique healthcare challenges, making it imperative to incorporate a variety of patient views within research domains.

### **2\. Cultural differences**

Internationally, patient engagement will likely reveal regional differences in individual needs and priorities due to factors such as treatment availability. Furthermore, due to disease distribution, it is important to collaborate with patients across all geographical locations to address a broader range of therapy areas.

### **3\.** **Equality**

Every patient should benefit from the progression of patient-centricity in healthcare, regardless of their demographic. By encouraging diverse patient engagement, future research may accommodate the needs of individuals from a variety of backgrounds and contexts, improving patient outcomes in an all-encompassing manner.

![](https://a.storyblok.com/f/166410/3980x4617/c474cbeb35/pexels-mikhail-nilov-6592640.jpg)

### **Identifying and recruiting patient representatives**

To identify a representative patient community, patient demographics must be clearly defined. These characteristics may include the gender, age, ethnicity, economic status, or education of the patient, just to name a few. It is important that patient engagement incorporates a wide range of these individual characteristics so that the average patient is represented.

A critical part of diversifying patient engagement is simplifying the recruitment process to allow for greater inclusion and mitigating factors such as socioeconomic status or technology that could impact patient contribution. In cases where the patient may be too sick or unaware of their circumstances, it is highly valuable to hear from family members or caregivers so that their experiences are still acknowledged by industry professionals.

An effective way to engage with patient communities is through collaborations with advocacy groups. Patient advocates provide direct support, knowledge, and assistance and are, therefore, acutely aware of patient perspectives and needs.By collaborating with advocates, healthcare professionals can capture patient insights without adding extra pressure to patients. Alternatively, some healthcare organisations, including the NHS, enable individuals to apply for a patient representative role. This type of patient recruitment involves a more thorough application process, requiring the completion of forms and sometimes even an interview. In order to encourage patient engagement, representatives are often offered monetary benefits as a reward for their contribution to the advancement of healthcare. (1)

![](https://a.storyblok.com/f/166410/4284x2856/9c04460c23/patient-diverse-engagement.jpg)

### **The role of pharma and healthcare agencies**

Following successful engagement activities, pharma companies must commit to elevating and disseminating patient insights throughout the industry to positively impact healthcare systems. That is why, at Synthesis, we are committed to transforming the wide-ranging insights provided by patients and caregivers into accessible forms of communication.

The potential rewards of including diversified patient engagements in research are vast. By promoting inclusive patient views, complex educational resources can be translated into accessible formats for wide-ranging audiences to understand. Furthermore, through enhanced awareness of representative patient needs, patient support and disease management programmes may provide more effective care and assistance across a greater spectrum of therapy domains, impacting healthcare globally.

* * *

Our team at Synthesis Health consists of specialist medical writers who share the motivation to boost healthcare outcomes for all stakeholders. Please contact us at [info@synthesishealth.co.uk](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml) to learn more about how we can support your patient advocacy and representative patient engagement activities.

* * *

References:

1. [https://clch.nhs.uk/get-involved/patient-representatives](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Motivations for Patient Engagement
# What motivates patients and caregivers to engage in health research?

Patient and public engagement is a cornerstone of contemporary health research aimed at breaking down barriers between research institutions and the communities they serve. While organisations have many reasons to seek patient engagement - from enhancing public trust to facilitating research co-creation - it's equally important to understand why patients want to reciprocate this engagement. So, what is motivating patients to participate in medical research?

![](https://a.storyblok.com/f/166410/6000x4000/76232c7956/patient-discussion.jpg)

### **1\. To represent a perspective and have a voice in research (1)**

Engaging in health research empowers patients by providing them with a platform to advocate for their needs. This involvement takes various forms - some patients may actively contribute to research co-design, while others may prefer to provide input on how to effectively communicate new findings to patient populations. Patients seek not only to be heard but also to exert influence over research outcomes that significantly impact their lives. Involvement in health research, particularly concerning conditions they have first-hand experience with, empowers patients by providing a platform to make meaningful contributions to areas where they may feel marginalised or overlooked.

### **2\. To advocate for unmet needs or underserved communities (2)**

Historically, marginalised groups have been overlooked in medical research. So, patients or patient representatives may seek to advocate for populations or conditions that are underserved, lack adequate services, are not well understood, or have needs that are not addressed. Engaging with patients from a diverse representation of communities is crucial to ensure an inclusive approach to healthcare.

### **3\. A desire to learn (3)**

Many patients who participate in research are motivated by a desire to learn. This may stem from a need to deepen their understanding of their condition or an interest in the research process shaping their treatment options. Research participation also allows patients to cultivate or enhance skills such as public speaking, meeting facilitation, and other research-related abilities that they might not encounter otherwise, making research participation a valuable learning opportunity.

### **4\. To build valuable relationships (3)**

Relationships play a pivotal role in motivating patient participation in health research. Endorsement from trusted healthcare professionals is one of the primary factors influencing a patient's decision to engage in research initiatives. Additionally, some patients perceive research participation as an opportunity to cultivate deeper connections with their care teams and the broader research community. Thus, a commitment to understanding and developing relationships with patients is crucial for enhancing patient engagement with research.

### **5\. To make a difference in people's lives or healthcare experiences (3)**

A significant number of research participants are driven by altruism; by a desire to contribute to the advancement of health research for the greater good. Rooted in a fundamental aspiration to effect positive change, these individuals aim to support the progress of science, address the needs of future generation and bridge demographic disparities in health research. Beyond personal motivations, patients engage in research with the goal of effecting genuine change within specific areas of care.

* * *

Patients are eager to participate in health research programs, motivated by a variety of factors: to improve their own health, contribute to their communities, acquire knowledge, honour their trusted care relationships, and advance healthcare research for the greater good. Engaging patients in research can support comprehensive and impactful research programs.

* * *

At Synthesis, we're passionate about bridging the gap between patients and industry to promote more effective and patient-centric approaches. From strategic input to specialist medical writing support, we offer end-to-end services that benefit patients and the wider industry. To learn more about how Synthesis can help you, [please get in touch.](https://synthesishealth.co.uk/work-with-us)

* * *

References:

1. Haesebaert J, Samson I, Lee-Gosselin H. et al. "They heard our voice!" patient engagement councils in community-based primary care practices: a participatory action research pilot study. _Res Involv Engagem_. 2020;6(54). doi:10.1186/s40900-020-00232-3

2. Shiyanbola OO, Kaiser BL, Thomas GR, Tarfa A. Preliminary engagement of a patient advisory board of African American community members with type 2 diabetes in a peer-led medication adherence intervention. _Res Involv Engagem_. 2021;7(1):4. doi:10.1186/s40900-020-00245-y

3. McCarron TL, Noseworthy T, Moffat K. et al. Understanding the motivations of patients: A co-designed project to understand the factors behind patient engagement. _Health Expect_. 2019;22(4):709-720. doi:10.1111/hex.12942


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient Communities and Pharma
# Unlocking the power of co-creation: Patient communities and pharma

Historically, the pharma industry has made decisions on behalf of patients throughout the development and product lifecycles of therapies and diagnostics. However, recent evolutions in the healthcare environment have empowered patients to play a more active role in healthcare decision-making, demanding a greater focus on patient-centricity and engagement within the industry. As a result, companies have increased their collaboration with patient communities, including patient groups, patient organisations, patient advocacy groups, expert patients, individual patients, caregivers and family members, to create meaningful value for patients, the industry, the healthcare system and society as a whole.

![](https://a.storyblok.com/f/166410/5472x3648/08b56e974d/patient-pharma-partner.jpg)

## **A natural partnership**

Patient communities and pharma/biotech companies share a universal vision: _helping every patient live longer and healthier lives through innovative medicines and diagnostics._

Managed correctly, relationships between pharma and patient communities can be mutually beneficial. While pharma possesses the scientific expertise, resources, and capacity to develop innovative therapies, patient communities offer invaluable insights into the lived experiences, challenges, perspectives, and unmet needs around illness, whether it be acute or chronic. By combining these complementary resources, pharma-patient partnerships ensure that the industry focuses on the fundamental vision that unites them.

From clinical trial design and implementation to drug development and market access, patient partnerships offer unparalleled value for pharma. Patients’ unique experiences, expertise and perspectives can be communicated company-wide and incorporated into the development of therapies and diagnostics. Patient communities benefit from leveraging pharma companies' resources, authority and expertise to promote awareness, secure funding, and drive significant change at a broader scale. Patients are empowered by having a voice during decision-making and often benefit in terms of healthcare provision as patient communities help to develop trial protocols and establish endpoints and solutions that matter most to patients and lead to treatments that effectively meet their needs. Patient communities also remain the ultimate conduit for communication between patients and pharma, offering direct channels to relay accurate and important information to patients.

An Accenture report of 4,000 patients in the U.S. and Europe showed (1):

- Most patients — **8** **4%** — believe that patient organisations should be working together with pharma companies

- **37%** of patients said that they believed pharma would better understand their needs if collaboration with patient organisations was improved

- Among the top benefits that patients believe would result from a better level of collaboration:

  - **56%** cited easier access to information on their condition and treatments

  - **56%** cited easier access to treatment

  - **54** **%** cited more personalised care

## Barriers to successful partnerships

Driven by a foundation of shared goals, long-term partnerships offer the commitment and perseverance to drive true system and policy change, generating results and traction that aren’t possible alone. But how symbiotic is the seemingly win-win relationship between pharma and patient communities? Not as extensive as it could be.

> **While 93% of pharma executives overwhelmingly agree that patient centricity is critical to their company’s future success, only 19% believe they have made meaningful progress to date (2)**

The pharma industry may hide behind compliance as an excuse not to engage with patient communities. In turn, those communities may fear a loss of independence regarding questions about financial donations and possibly distrust pharma’s motives.

However, rather than thinking of regulatory limitations, pharma must consider untapped partnership opportunities that leverage data, analytics, and real-life insights that can, collectively, improve patient care. By continuously listening and harnessing the power of the patient voice, co-creating solutions and turning insights into specific actions, pharma can meaningfully partner with the patient community to simultaneously improve the patient experience whilst reaping commercial benefits.

## The ingredients for a successful partnership

Regardless of whether the patient community and advocacy space is crowded or there are only one or two key players, which is common in rare diseases, the approach should remain the same - establish a relationship built on trust and transparency from the start. This ensures complete alignment and understanding of the goals, expectations and deliverables of what each party anticipates from the relationship. Patient communities can alleviate their members' concerns about losing independence by demonstrating transparency and communicating the impact of the partnership.

Acknowledging that patient engagement is no longer a ‘nice-to-have’ but a fundamental ‘must-do’ for pharma is crucial in acquiring longer-term investment for success in an ever-increasing patient-focused future.

* * *

Synthesis is a specialist medical communications agency that provides meticulous editorial support across all stages of medical manuscript development and submission. Contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to find out more about how we can help you develop publications that showcase the crucial insights and co-creation of solutions gained from patient partnerships to lobby for change.

* * *

References:

1. [https://newsroom.accenture.com/news/better-collaboration-between-pharma-and-patient-organizations-would-improve-patient-care-accenture-study-finds.htm](https://newsroom.accenture.com/news/better-collaboration-between-pharma-and-patient-organizations-would-improve-patient-care-accenture-study-finds.htm)

2. [https://www.zs.com/insights/how-pharma-companies-and-patients-can-become-true-partners](https://www.zs.com/insights/how-pharma-companies-and-patients-can-become-true-partners)


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient Partnerships in Healthcare
# The power of patient partnerships: Why you should publish patient engagement outputs

In recent years, patient engagement has become a driving force in the pharmaceutical industry, encouraging collaboration, communication and advocacy with patient groups to empower patients, enhance clinical research, and improve overall healthcare outcomes. While many pharma companies actively engage in patient engagement initiatives, the insights and results of these collaborations may not be formally published to benefit patients and the wider pharmaceutical industry.

So, why should pharma consider publishing the outputs of their patient partnership projects?

### **1\. Amplify patient voices**

Patients are the core stakeholders in healthcare. By publishing their unique experiences, perspectives and insights, pharma companies amplify patient voices and ensure their contributions are heard, acknowledged, and later integrated into decision-making processes. Not only can this meaningfully impact research and development processes, but it also demonstrates a pharma company’s commitment to patient engagement, building transparency, credibility, and trust between patients and wider industry stakeholders.

### **2\. Improve patient outcomes**

Published insights from patients can be accessed and incorporated into decision-making processes across the industry to improve patient outcomes. This patient-centric approach enhances research quality and increases the likelihood of developing treatments that better address patient needs and preferences.

### **3\. Disseminate knowledge**

Publishing valuable insights from patient engagement activities can be pivotal in disseminating knowledge throughout the healthcare industry. As a credible and transparent resource, these insights enable healthcare professionals to access firsthand accounts of patient needs and challenges to foster a deeper understanding of diseases, treatment outcomes, and healthcare delivery to make more informed decisions and influence healthcare practices to better meet patient needs.

![](https://a.storyblok.com/f/166410/4272x2848/8bb6437fed/sharing-knowledge.jpg)

### **4\. Drive greater impact**

Partnerships between patient communities and pharma offer the commitment and perseverance to drive true system and policy change, generating results and traction that aren’t possible alone. Published insights that shed light on patients’ unmet needs, challenges, preferences and barriers to care can provide valuable evidence to policymakers and regulatory agencies to drive systemic change and shape policies that align with patient interests.

### **5\. Encourage innovation and collaboration**

Publishing outputs from patient partnerships can encourage other pharma companies and industry stakeholders to adopt patient engagement practices, ultimately fostering a culture of innovation and collaboration to drive advancements in patient care and research.

### **6\. Enhance reputation**

By documenting patient partnership projects in published papers, pharma companies showcase their commitment to supporting patients and patient organisation partners as they grow and thrive to better serve their community. Not only does this resonate positively with patients, healthcare providers, regulators and investors, fostering trust and credibility in the industry, but it can also elevate a company's reputation as one that values patient engagement and actively supports patient advocacy.

![](https://a.storyblok.com/f/166410/5895x3930/fdfe35cfed/pharma-reputation.jpg)

Patients are ready to share their perspectives and experiences to move the needle and create a better future for all. While pharma possesses the scientific expertise, resources, and capacity to develop innovative therapies, patient communities offer invaluable insights into the lived experiences, challenges, perspectives, and unmet needs around illness, whether it be acute or chronic.

Publishing the insights from these collaborations is a crucial step for pharma companies to revolutionise the pharmaceutical industry's approach to patient engagement. Embracing patient engagement initiatives and formalising the insights and experiences shared by patients is a testament to a pharma company's commitment to patient welfare and a transformative step towards a more patient-centred future to improve overall healthcare outcomes.

* * *

Synthesis is a specialist medical communications agency that provides meticulous editorial support across all stages of medical manuscript development and submission. Contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to find out more about how we can help you develop publications that showcase the crucial insights and co-creation of solutions gained from patient partnerships to lobby for change.

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Health Literacy Insights
# Health literacy: The gatekeeper for patient health outcomes

## What is ‘health literacy’?

Health literacy, the ability to understand and apply health-related information, is fundamental for informed decision-making in healthcare. Alarmingly, up to 43% of adults struggle to understand healthcare information, with this figure rising to 61% when numerical values are involved. (1)

Research has shown that low health literacy is associated with poorer health outcomes, with effects even more pronounced in individuals from disadvantaged backgrounds. (2) As such, this creates problems at both the individual level due to reduced quality of life, as well as the societal level, as healthcare costs are elevated. Health literacy may, therefore, be described as the gatekeeper for how much patients can actively contribute to their own care.

## The consequences of poor patient communication

With the aim of improving patient care, regulatory bodies have urged clinical datasets to be more readily available. However, patients still face challenges in understanding what industry-led trial results mean for them specifically. This disparity often results in patients struggling to understand treatment instructions, complete medical forms accurately, and adhere to recommended lifestyle changes – the consequences of which could be severe. Research has revealed significant shortcomings in treatment adherence across various conditions, demographics and treatment types (3-7), emphasising the pivotal role of health literacy in fostering improved health outcomes.

## Creating patient-centred material

Medical writers act as a source of information transmittance, enhancing patient experience at two critical levels: improving access to information and patient understanding once they attain that information. The more accessible a text is for a patient, the more likely they will benefit from its content. In this way, hospitalisations and medical risks are also reduced. (2)

Medical writers create patient-optimised materials surrounding clinical research publications, review articles, medical reports and policy briefs. Their history of working alongside patients allows them to utilise their expertise for best practices in translating scientific concepts into patient-centric terms, making the following adaptations:

- **Patient-specificity** \- personalised documents with relevant information on specific conditions, disease stages and treatment plans.

- **Integration**\- drawing on research across the drug development life cycle, their implications for different life domains and communicating key take-home messages.

- **Simplified language**\- conscientiously converting scientific jargon to layman’s terms.

- **Adjusted formatting and design** \- making font sizes and layouts less overwhelming.

- **Visual aids** \- figures, pictograms and infographics.


![](https://a.storyblok.com/f/166410/6000x4000/f6d16e8538/patient-reading.jpg)

## The benefits of involving medical writers in the healthcare delivery process

Over 1/3 of the EU adult population reported having a chronic health problem in 2022. (8) This prevalence of chronic health issues underscores the urgency of effective healthcare delivery amidst resource constraints. However, patients often retain only half of the information provided during healthcare appointments, leading to unresolved concerns and potential misinformation sourced from the internet. (9)

eHealth literacy, information provided by online resources, is a significant factor in mediating the relationship between health literacy and altered health-related behaviours. (10) By incorporating the above components, medical writers can provide reliable information whilst negating the negative emotional spiral that ensues when patients encounter overwhelmingly intricate information that further exacerbates interpretation difficulties. This enables patients to make informed lifestyle and treatment decisions that favour their long-term health outcomes.

Importantly, the impact medical writers have is bidirectional. Medical writers can inspire innovation by informing academic researchers and industry stakeholders on patient views and extraneous variables impacting outcomes, which may be responsible for non-significant results, resulting in improved likelihood of journal publication, and more so for those with a higher impact factor. (11) With increased understanding, patients can proactively seek treatment availability through direct contact with pharmaceutical companies, improving corporate outreach.

Patient-centric writing increases patient engagement, allowing them to build agency in managing their health. This improves patient satisfaction and health trajectories such that wait-listed individuals can be seen sooner, enhancing public access to services and commercial organisations.

## Medical writers as mediators in the medical research and treatment dissemination process

Patient-centred approaches are becoming increasingly critical to the medical field’s development. The ultimate goal of healthcare research is to improve the lived experiences of individuals and reduce the socioeconomic burden of ill health. However, without effective communication with patients, improvements to patient trajectories are inherently limited. As experts in this field, medical writers are best placed to incorporate patient-centricity into current healthcare strategies, whether at the level of academia, industry, or patient associations.

* * *

Contact us at [info@synthesishealth.co.uk](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml) today to explore how our dedicated medical writers can expand the reach of your work, augment its impact and spark innovation that generates meaningful change in patients’ lives.

* * *

References:

01. Rowlands G, Protheroe J, Winkley J, Richardson M, Seed PT, Rudd R. A mismatch between population health literacy and the complexity of health information: an observational study. _Br J Gen Pract_. 2015;65(635):e379-e386. doi:10.3399/bjgp15X685285

02. [https://www.cdc.gov/healthliteracy/index.html](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)

03. López San Román A, Bermejo F, Carrera E, Pérez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. _Rev Esp Enferm Dig_. 2005;97(4):249-257. doi:10.4321/s1130-01082005000400005

04. Sharma T, Kalra J, Dhasmana D, Basera H. Poor adherence to treatment: A major challenge in diabetes. _J Indian Acad Clin Med_. 2014;31(40):40

05. Tavares NU, Bertoldi AD, Thumé E, Facchini LA, França GV, Mengue SS. Factors associated with low adherence to medication in older adults. _Revista de saude publica_. 2013;47:1092-101. doi: 10.1590/S0034-8910.2013047004834

06. Vuorilehto MS, Melartin TK, Riihimäki K, Isometsä ET. Pharmacological and psychosocial treatment of depression in primary care: low intensity and poor adherence and continuity. _J Affect Disord_. 2016;202:145-52. doi: 10.1016/j.jad.2016.05.035

07. Gadallah MA, Boulos DN, Dewedar S, Gebrel A, Morisky DE. Assessment of rheumatoid arthritis patients’ adherence to treatment. _Am J Med Sci._ 2015;349(2):151-6. doi: 10.1097/MAJ.0000000000000376

08. [https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Self-perceived\_health\_statistics](file:///Users/elliecollins/Library/Group%20Containers/UBF8T346G9.Office/TemporaryItems/msohtmlclip/clip_filelist.xml)

09. Laws MB, Lee Y, Taubin T, Rogers WH, Wilson IB. Factors associated with patient recall of key information in ambulatory specialty care visits: Results of an innovative methodology. _PLoS One._ 2018;13(2):e0191940. doi: 10.1371/journal.pone.0191940

10. Lans A, Schwab JH. Health Literacy in Orthopaedics. _J Am Acad Orthop Surg._ 2023;31(8):382-388. doi:10.5435/JAAOS-D-22-01026

11. Evuarherhe O, Gattrell W, White R. et al. Professional medical writing support and the quality, ethics and timeliness of clinical trial reporting: a systematic review. _Res Integr Peer Rev._ 2019;4(14). doi: 10.1186/s41073-019-0073-7


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Diversity in Clinical Trials
# Building health equity: How can we mitigate barriers to diverse clinical trial participation?

As the industry increasingly recognises the need to address health disparities among communities that have been previously underrepresented in medical research, diversity and equality have become key priorities in the medical world. Of course, this is a progressive stride towards achieving health equity, but as industry professionals, we must ask ourselves: are we doing enough to mitigate the continued lack of diversity in clinical trials?

## **Acknowledging the ongoing problem**

The marginalisation of groups in clinical trials is not just a historical issue—it remains a persistent problem in pharma and healthcare.

Although the inclusion of women in clinical research has risen since the 1990s, a lack of gender diversity is still evident in various therapy areas, such as psychiatry. (1) Despite women accounting for 60% of patients in psychiatric settings, a study covering 1,433 Phase 1-3 clinical trials conducted from 2016 to 2019 found that only 42% of participants were female. (2)

Furthermore, people of colour continue to be disproportionately underrepresented in clinical trials. In the US Food and Drug Administration 2020 drug trials snapshots summary, selected subpopulation demographics were reported from the trials of 53 newly approved drugs. It was noted that only 25% of the total 32,000 participants were of diverse racial and ethnic descent, with 11% being Hispanic, 8% Black or African American, and 6% Asian, while the other 75% of trial participants were White. (3)

It is important to note that ongoing gaps in clinical trial diversity extend beyond gender and ethnicity, with considerable exclusion of patients due to their age, sexual orientation, geographic location, and socioeconomic status, just to name a few.

The underrepresentation of certain populations in healthcare research directly impacts health equity, defined by the World Health Organization as “the absence of unfair, avoidable or remediable differences among groups of people, whether those groups are defined socially, economically, demographically, or geographically or by other dimensions of inequality”. (4) Novel treatments developed in inadequately represented cohorts may be less effective or induce contrasting adverse effects in underserved patient groups. Consequently, the pharmaceutical industry cannot provide all individuals with the personalised care necessary for achieving optimal health and wellbeing, compromising universal health equity.

## **Key barriers to diverse clinical trial participation**

So, what are the key barriers that influence the participation of underrepresented communities and result in poor clinical trial diversity?

There is a clear lack of awareness among patients regarding what clinical trials entail, and their value, for both the individual and the wider population. Unfamiliarity with clinical research may lead to fear and stigma around participating, leading to a sense of mistrust among patients. (5-6) Often, this lack of awareness and trust stems from insufficient educational resources for patients, and even physicians, within underrepresented groups. (7)

Moreover, participating in clinical research requires time and can be costly. Geographically isolated individuals, those with limited mobility, or people with a lower socioeconomic status may be unable to participate in trials, even if they are inclined to do so. Similarly, cultural factors such as language and beliefs may hinder clinical trial involvement. (7)

## ![](https://a.storyblok.com/f/166410/5218x3479/e3b89c0c3e/barrier.jpg)**Mitigating barriers to advance health equity**

Beyond raising awareness of the ongoing challenges, medical communications can be powerful in identifying and implementing tangible, scalable solutions to promote health equity for all.

At Synthesis, with our expertise in patient advocacy and representative patient engagement, we can support inclusive clinical trial participation through three principal strategies: (5-7)

1. **Diverse patient engagement**: We reach underrepresented communities by collaborating with local advocacy and patient groups in diverse regions to increase awareness of clinical trial opportunities and build trust among patients, while reducing fears about participation.

2. **Communicate unmet patient needs**: We regularly collect insights from underserved patients and disseminate these insights across the industry to raise awareness of unmet needs.

3. **Patient materials**: We develop lay-friendly, culturally appropriate educational materials tailored to diverse audiences to improve their understanding of clinical trials and enhance recruitment, whilst ensuring clarity and conciseness to improve accessibility.


Collaborating across the industry at both strategic and practical levels to shape healthcare policy is critical to addressing additional challenges faced by underrepresented groups in clinical research.

Our team of specialist medical writers at Synthesis Health is committed to promoting collaboration between pharmaceutical companies and stakeholders to drive systematic change for all by circulating diverse patient insights and learnings throughout the industry.

Please contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to learn more about how we can support your patient engagement activities.

* * *

**References**

1. National Institutes of Health. (1993). NIH Revitalization Act of 1993 Public Law 103-43

2. SosinskyAZ, Rich-Edwards JW, Wiley A, Wright K, Spagnolo PA, Joffe H. Enrollment of female participants in United States drug and device phase 1-3 clinical trials between 2016 and 2019. _Contemp Clin Trials_. 2022;115:106718. doi:10.1016/j.cct.2022.106718

3. US Food and Drug Administration Drug Trials Snapshots Report (2020) [https://www.fda.gov/media/145718/download?attachment](https://www.fda.gov/media/145718/download?attachment)

4. Health equity, World Health Organization [https://www.who.int/health-topics/health-equity#tab=tab\_1](https://www.who.int/health-topics/health-equity#tab=tab_1)

5. Clark LT, Watkins L, Piña IL, et al. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers \[published correction appears in Curr Probl Cardiol. 2021 Mar;46(3):100647. doi: 10.1016/j.cpcardiol.2020.100647\]. _Curr Probl Cardiol_. 2019;44(5):148-172. doi:10.1016/j.cpcardiol.2018.11.002

6. Bae AS. Key barriers against racial and ethnic minority participation in U.S. clinical trials. Int J Clin Trials 2022;9(3):227-33

7. Building Health Equity By Minimizing Barriers To Clinical Trial Participation [https://www.clinicalleader.com/doc/building-health-equity-by-minimizing-barriers-to-clinical-trial-participation-0001](https://www.clinicalleader.com/doc/building-health-equity-by-minimizing-barriers-to-clinical-trial-participation-0001)


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient-Reported Outcomes Explained
# Patient-Reported Outcomes (PROs) — what they are and why they matter

In today’s healthcare environment, it is more important than ever to hear and integrate patient perspectives into medicine research and development processes. Patient-reported outcomes, or PROs, are reports directly from patients regarding their health status, free from any influence by healthcare professionals. Clinical trials that prioritise PROs as primary endpoints or use them to complement other primary outcomes, such as survival rate, gain a strategic advantage: they ensure research aligns with the outcomes that matter most to patients. (1)

**Ultimately, only the patient can comprehend the true impact of their condition.**

PROs can capture a wide range of patient insights, from simple ratings of pain severity or treatment satisfaction to broader considerations, such as how their condition affects their quality of life, the symptoms they experience, or any challenges they encounter with their care. (1) Therefore, adopting both quantitative and qualitative approaches to measure these metrics is crucial for gaining a comprehensive understanding of diverse patient needs and feelings.

Patient-reported outcome measures (PROMs) are tools used to determine patients’ perspectives on their health, primarily through self-assessment questionnaires. Some of these measures are universally applicable across various conditions, such as the EQ‐5D, which includes dimensions like anxiety and depression. Others are more disease-specific, for example, the PRO-CTCAE questionnaire for cancer patients.Together, these self-report methods enable clinicians to gather patient insights within specific therapy areas and compare these data across conditions. (2,3)

So, what is the value of PROs, and why should their outputs be disseminated across the industry?

The primary benefit of PROs is that they support **true patient-centricity**.

![](https://a.storyblok.com/f/166410/6720x4480/cf65eb96b1/clinical-trial.jpg)

With our robust drug discovery and development pathways, countless clinically effective drugs are now available for patients. However, many of these treatments are not always patient-friendly. Let’s consider the combined pill, for example. This has proven to be over 99% effective in preventing pregnancy in sexually active women and people with periods when used correctly, according to the NHS. (4) Despite the efficacy of this contraceptive, many individuals switch pills or discontinue the pill altogether due to its adverse effects on their body and mind, with mood changes being a common reason. (5)

This area of women’s health would, therefore, benefit significantly from PROs to raise awareness of the challenges women face when taking the combined pill. As healthcare professionals, we must go beyond sharing these learnings within the industry and incorporate them into decision-making processes to shape the future development of similar contraceptives that better align with patient needs, empowering them to have a healthy sex life with fewer adversities.

In addition to amplifying patient voices to drive patient-focused drug development, PROs play a crucial role in enhancing the safety and tolerability of novel therapies. This is evident in the field of oncology, particularly with the emerging treatments in malignant haematology and oncology. Patient-reported symptomatic adverse effects will likely aid in the development of these cancer therapies, strengthening the validity of existing safety reports conducted by clinicians and providing longitudinal evidence of toxicities in real-world settings. (6)

With patient safety at the forefront of our healthcare system, PROs are a vital tool in modern healthcare. Moreover, if patient-reported outcomes are central to our medicine development lifecycle, pharmaceutical companies stand to gain financially by delivering drugs tailored to patient interests, benefiting all stakeholders.

At Synthesis, we understand that every patient's experience, priorities, and needs are unique and personal. That is why our team of specialist medical writers is dedicated to circulating their diverse insights throughout the industry to improve health outcomes inclusively. Contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to learn how we can support your partnerships with patients and their advocates throughout the entire drug development process.

* * *

**References:**

1. Weldring T, Smith SM. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs). _Health Serv Insights_. 2013;6:61-68. Published 2013 Aug 4. doi:10.4137/HSI.S11093

2. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). _Qual Life Res_. 2011;20(10):1727-1736. doi:10.1007/s11136-011-9903-x

3. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Annals of Oncology. 2022;33(9):878-892. doi:10.1016/j.annonc.2022.04.007

4. What is the combined pill? [https://www.nhs.uk/contraception/methods-of-contraception/combined-pill/what-is-it/](https://www.nhs.uk/contraception/methods-of-contraception/combined-pill/what-is-it/)

5. Johansson T, Vinther Larsen S, Bui M, Ek WE, Karlsson T, Johansson Å. Population-based cohort study of oral contraceptive use and risk of depression. Epidemiology and Psychiatric Sciences. 2023;32:e39. doi:10.1017/S2045796023000525

6. Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). _Am Soc Clin Oncol Educ Book_. 2016;35:67-73. doi:10.1200/EDBK\_159514


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient-Centric Drug Development
# Patient insight-led drug development: Ensuring patients are at the centre of clinical trial design

The journey of drug development is a step-by-step process, offering numerous opportunities to harness invaluable patient insights and shape future treatments to best align with their needs. Although patient-centricity is well-established in healthcare, it is critical that we, as industry professionals, integrate these perspectives into clinical decision-making to advance the patient experience of illness.

The first step in ensuring clinical trials are patient-focused and accessible to all is gathering diverse patient feedback. An effective way to hear and understand patient views is through building partnerships that foster trust between patients and pharmaceutical companies. Specific approaches for collaboration include focus group discussions with local patient communities, surveys, and exit interviews. (1,2) By conducting engagement activities, healthcare providers can collect extensive patient insights throughout the clinical development lifecycle. This real-world data may include patients' experiences with the study design, the progression of their condition, their quality of life, any burdens related to their treatment, disease, or the clinical trial, their treatment preferences, and their perspectives on the benefit-risk ratio of the treatment. (3-6)

Patients' unique expertise can be incorporated into clinical decisions related to the development of novel therapies and diagnostics. Healthcare professionals face a range of decisions in clinical settings, such as designing the trial protocol, selecting the treatment arm, assessing health and safety risks, determining which biomarkers to evaluate, and identifying clinical outcome assessments, among others. (7-9) These medical decisions often lack a clear ‘right or wrong’ answer, as what works for one patient may not work for another. Therefore, clinicians must carefully weigh the advantages and disadvantages of each option to ensure that patient needs and values are considered inclusively. (10) Fortunately, technological advancements have resulted in the creation of clinical decision support systems: ever-evolving tools that empower clinicians to make better-informed decisions in both clinical development and patient care. (11)

![](https://a.storyblok.com/f/166410/6000x4000/f6d16e8538/patient-reading.jpg)Implementing patient-guided decision-making in clinical development plans has profound benefits for all stakeholders. Placing patients at the core of treatment development not only encourages true patient-centricity in our healthcare systems, leading to better patient-reported health outcomes, but also offers various advantages for pharmaceutical companies. Firstly, incorporating the patient voice into healthcare research positively impacts clinical trials by enhancing patient recruitment and retention while aligning research aims and study endpoints with patient priorities, ultimately resulting in the development of therapies that effectively address their needs.Furthermore, adopting patient-led decision-making in clinical trials boosts the financial gains of pharma companies; the likelihood of successfully launching an investigational drug is greater, the time to market is reduced, and there is an overall enhanced return on investment. (12)

As healthcare professionals, it is our responsibility to ensure that patients’ lived experiences are considered in clinical decision-making. Future research should, therefore, focus on developing a systematic approach to involve patients seamlessly in clinical development plans. Some progress has already been made, as demonstrated by TransCelerate Biopharma Inc.’s Patient Experience Initiative, which explored frameworks to promote early patient collaboration in the drug development lifecycle. Nevertheless, there is still a long way to go. (13)

At Synthesis, our team of specialist medical writers is committed to driving meaningful change for patients by ensuring their voices are amplified across the industry and translated into tangible action. Contact us at info@synthesishealth.co.uk to learn how we can support your partnerships with patients and their advocates throughout the entire drug development process, providing valuable insights to guide your decision-making in clinical settings.

* * *

**References**

01. Patient Engagement: Technical Series on Safer Primary Care, World Health Organization 2016 [https://iris.who.int/bitstream/handle/10665/252269/9789241511629-eng.pdf](https://iris.who.int/bitstream/handle/10665/252269/9789241511629-eng.pdf)

02. Matza LS, Stewart KD, Landó LF, Patel H, Boye KS. Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes. _Patient_. 2022;15(3):367-377. doi:10.1007/s40271-022-00578-8

03. Lucas R, Wang SF, Riley J, Pepper J, Cowie M. Patient experience in clinical trials: results of a survey. _Eur J Heart Fail_. 2018;20(3):612-614. doi:10.1002/ejhf.1105

04. How can the value of patient engagement be quantified and measured? [https://pharmaphorum.com/patients/how-can-value-patient-engagement-be-quantified-and-measured](https://pharmaphorum.com/patients/how-can-value-patient-engagement-be-quantified-and-measured)

05. Kleykamp BA, Dworkin RH, Turk DC, et al. Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations. _Pain_. 2022;163(6):1006-1018. doi:10.1097/j.pain.0000000000002475

06. Masri HE, McGuire TM, Dalais C, van Driel M, Benham H, Hollingworth SA. Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies. _J Med Libr Assoc_. 2022;110(2):185-204. doi:10.5195/jmla.2022.1306

07. Choodari-Oskooei B, Thwin SS, Blenkinsop A, Widmer M, Althabe F, Parmar MK. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial. _Clin Trials_. 2023;20(1):71-80. doi:10.1177/17407745221136527

08. Risk Considerations, Queen Mary University of London [https://www.jrmo.org.uk/performing-research/conducting-research-with-human-participants-outside-the-nhs/risk-considerations/](https://www.jrmo.org.uk/performing-research/conducting-research-with-human-participants-outside-the-nhs/risk-considerations/)

09. Califf RM. Biomarker definitions and their applications. _Exp Biol Med (Maywood)_. 2018;243(3):213-221. doi:10.1177/1535370217750088

10. Krist AH, Tong ST, Aycock RA, Longo DR. Engaging Patients in Decision-Making and Behavior Change to Promote Prevention. _Stud Health Technol Inform_. 2017;240:284-302.

11. Chen Z, Liang N, Zhang H, et al. Harnessing the power of clinical decision support systems: challenges and opportunities. _Open Heart_. 2023;10(2):e002432. Published 2023 Nov 28. doi:10.1136/openhrt-2023-002432

12. Levitan B, Getz K, Eisenstein EL, et al. Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. _Ther Innov Regul Sci_. 2018;52(2):220-229. doi:10.1177/2168479017716715

13. TransCelerate Biopharma Toolkits Core Team, Elmer M, Florek C, et al. Amplifying the Voice of the Patient in Clinical Research: Development of Toolkits for Use in Designing and Conducting Patient-Centered Clinical Studies. _Ther Innov Regul Sci_. 2020;54(6):1489-1500. doi:10.1007/s43441-020-00176-6


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient Advocacy in Rare Diseases
# Transforming the rare disease landscape: The essential role of patient advocacy groups and pharma

According to the UK government, one in every 17 individuals will be affected by a rare disease during their lifetime. These conditions, each affecting fewer than one in 2,000 individuals, create significant gaps in the current healthcare landscape. As a result, many rare disease patients face a lack of approved treatments, leading to potentially life-threatening outcomes. (1)

Despite these challenges, patient advocacy groups (PAGs) offer valuable opportunities to overcome barriers to rare disease awareness and research.

PAGs bridge the gap between patients, their caregivers and families, and the pharmaceutical industry, providing resources and support to those living with a disease while engaging in various aspects of clinical research. By fostering relationships with rare disease patients, advocacy groups help create a sense of community among individuals who might otherwise face their condition in isolation.Furthermore, these groups contribute to advocating for research to address knowledge gaps in rare diseases, establishing evidence-based practices, and facilitating recruitment and trial designs to accelerate the discovery and development of patient-friendly therapies. (2)

![](https://a.storyblok.com/f/166410/5040x3360/0d406a25ef/community-hands.jpg)So, what are the main goals of PAGs in rare disease research?

With patient-centricity and engagement at the forefront of our healthcare system, PAGs are primarily motivated by the goal of improving the patient journey in rare diseases. This complex, multifaceted goal includes elevating disease awareness and recognition, providing educational resources to both healthcare professionals and rare disease families, advocating for funding, informing health policies to drive systemic changes that align with patient needs, and ensuring that the patient voice is central at every stage of the drug development lifecycle. (2,3)

As a by-product of their dedication to patients, PAGs also assist pharmaceutical companies in the clinical and commercial development of novel treatments. This support includes accumulating real-world evidence and providing guidance on navigating regulatory pathways. (4)

Unfortunately, advocacy groups' efforts to improve the lives of patients with rare diseases are often limited by insufficient funding and attention from researchers and industry leaders. (2) To advance our knowledge in this field and increase the availability of high-efficacy medicines for deserving patients, the pharmaceutical industry must shift its focus toward rare disease research. Healthcare and pharmaceutical companies should partner with PAGs to better understand patients’ and caregivers’ lived experiences, overcome barriers to care, and, importantly, build trust within rare disease communities. Through productive collaboration, mutually beneficial partnerships can be established—patients can contribute to much-needed research by participating in clinical trials, enabling researchers to develop patient-centric treatments with a higher likelihood of approval.

Since rare diseases affect small populations, gaining valuable patient insights is critical. At Synthesis, we believe every patient deserves optimal healthcare and treatment options, regardless of how rare their condition may be. That is why our team of specialist medical writers is dedicated to building strong partnerships that foster empathy and trust between patients and the pharmaceutical industry, helping to mitigate barriers to care and improve health outcomes for all. Contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to learn how we can help disseminate knowledge to promote awareness among industry leaders and support your patient engagement and advocacy initiatives.

* * *

**References**

1. The UK Rare Diseases Framework [https://www.gov.uk/government/publications/uk-rare-diseases-framework/the-uk-rare-diseases-framework](https://www.gov.uk/government/publications/uk-rare-diseases-framework/the-uk-rare-diseases-framework)

2. Patterson AM, O’Boyle M, VanNoy GE, Dies KA. Emerging roles and opportunities for rare disease patient advocacy groups. Therapeutic Advances in Rare Disease. 2023;4. doi:10.1177/26330040231164425

3. Sharma R., Ahmed, S., Campagnari, J. _et al._ Embedding Patient-Centricity by Collaborating with Patients to Transform the Rare Disease Ecosystem. _Pharm Med_ **37**, 265–273 (2023). [https://doi.org/10.1007/s40290-023-00474-y](https://doi.org/10.1007/s40290-023-00474-y)

4. Gentilini A, Miraldo M. The role of patient organisations in research and development: Evidence from rare diseases. _Soc Sci Med_. 2023;338:116332. doi:10.1016/j.socscimed.2023.116332


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient Engagement Insights
13 April 2025

# Behind the psychology of patient engagement: How to unlock motivators and overcome barriers

With our evolving patient-centric healthcare system, patients are increasingly shifting from passive recipients to active participants in their care. To establish patient engagement as a standard practice across diverse clinical settings, activities must be accessible and designed to meet the unique needs of individuals from all backgrounds. (1)

For patients, choosing to engage in their personal healthcare journey can be overwhelming—this choice involves a wide range of complex cognitive and emotional processes. Psychological factors, such as motivation, trust, and self-efficacy, play a critical role in shaping patient collaboration with industry professionals. (2,3) Although some progress has been achieved in this field—for example, Graffigna and Barello have described the Patient Health Engagement model, an innovative tool that quantifies the psychological aspects of active participation—research into the psychology underlying patient engagement is sparse. (3) By leveraging evidence-based psychological techniques, we, as an industry, can empower patients in their decision to engage in their care, thereby benefiting diverse stakeholders.

**What motivates patients?**

To enhance the psychological drive behind patient involvement, we must unlock well-established motivators. Research has identified extensive motives that inspire patients to work alongside their healthcare providers and take control of their care. These range from personal ambitions—such as self-fulfilment, compensation, and educational opportunities—to more altruistic reasons, including improved health outcomes for future patients and stronger patient-provider partnerships. (2,4)

Translating this knowledge into action by adopting patient-centric approaches that motivate patients and underline greater participation is essential.

The foundation of all patient engagement is built on communication. By disseminating lay-friendly, accurate information across widely accessible platforms, we create opportunities to improve health literacy and inform patients about peer groups, upcoming clinical trials, and their value at a personal and community level. (5)

Taking this a step further, the way in which we communicate with patients matters. Leveraging effective communication tools—for example, sharing relatable anecdotes—can make the healthcare experience less intimidating and reach broader patient populations. These skills help build trust and close the gap between patients and providers. (6)

![](https://a.storyblok.com/f/166410/8063x5375/92db853ae3/patient-understanding.jpg)

**Why are patients hesitant to participate?**

An alternative route to enhancing patient involvement is to mitigate persisting psychological barriers to their contribution. Maybe you know someone with a phobia of needles, or perhaps someone who dislikes the dentist—even these routine medical exposures can trigger anxiety for many. So, when individuals are diagnosed with conditions that threaten their overall health or quality of life, they typically experience negative emotions. These psychological factors may reduce patients’ willingness to engage in their healthcare journey, often due to a lack of trust in providers or disease-related stigma. More specifically, fear of interventional risks (e.g., side effects or symptom recurrence) and uncertainty about their treatment group—whether they are receiving the placebo or the study drug—may contribute to patient withdrawal from clinical settings. (7)

**Leveraging drivers and overcoming barriers**

Understanding the psychological drivers and barriers to participation is essential to develop effective strategies to promote patient engagement. This paves the way for behavioural science: the translation of scientific knowledge about human behaviour into practical, evidence-based approaches that influence positive action. (8)

Firstly, creating an environment of psychological safety, where patients feel comfortable voicing their needs and concerns or asking questions, is imperative for successful two-way interactions that foster mutual respect. (9) Additionally, adopting a shared decision-making approach to patient care can enhance involvement. According to the NICE shared decision-making guidelines (2019), involving patients in decisions regarding their treatment plan empowers them with the knowledge of potential benefits and risks, enabling them to make informed, supported choices. (10)

A more strategic approach to encourage patients to take an active role in managing their health is through positive reinforcement. This is a concept in which an individual is rewarded for favourable behaviour. In turn, they develop an association between the two, increasing their likelihood of repeating the behaviour in anticipation of the reward. (11) The reward could be as simple as a healthcare provider acknowledging the patient’s engagement with a kind word. Alternatively, patients may seek a peer support group to gain a community so they feel less alone in their condition.

Alongside technological advances, gamification (applying game-inspired features to real-world scenarios) has become a well-established method of positive reinforcement in healthcare.

For children, adolescents, and young adults with diabetes, self-monitoring blood glucose levels is a daily necessity. Given the frequency of recommended testing, it can feel like a chore for many. In response, Bayer HealthCare developed the DIDGET system to motivate adherence by integrating blood glucose monitoring into video gaming. When individuals consistently test their blood glucose, they earn benefits that can be used in video games, thereby reinforcing positive testing behaviour. This is a valuable tool, particularly for young patients, as adopting safe blood glucose monitoring practices early on leads to effective, deep-rooted habits. (12)

_Image of Bayer's Didget blood glucose meter from_ [_newatlas.com_](http://newatlas.com/) _:_  _![](https://a.storyblok.com/f/166410/1920x1280/041c9b2f31/bayer-didget.webp)_ At Synthesis, we recognise that promoting patient engagement is a complex, multifaceted process requiring effort from multiple stakeholders. Our team of specialist medical writers is dedicated to providing patient-friendly, accurate information that empowers patients, improves health literacy, and raises awareness of engagement activities to drive participation. Beyond this, we believe in the power of effective collaboration between research teams and patient engagement and advocacy groups to build trust and strengthen patient partnerships within the industry. Contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to learn how we can support your partnerships with patients and their advocates, leveraging simple communication techniques and positive reinforcement strategies to modernise clinical settings.

* * *

**References**

01. Higgins T, Larson E, Schnall R. Unraveling the meaning of patient engagement: A concept analysis. _Patient Educ Couns_. 2017;100(1):30-36. doi:10.1016/j.pec.2016.09.002

02. Raab C, Gambashidze N, Brust L, Weigl M, Koch A. Motivation for patient engagement in patient safety: a multi-perspective, explorative survey. _BMC Health Serv Res_. 2024;24(1):1052. Published 2024 Sep 11. doi:10.1186/s12913-024-11495-x

03. Graffigna G, Barello S. Spotlight on the Patient Health Engagement model (PHE model): a psychosocial theory to understand people's meaningful engagement in their own health care. _Patient Prefer Adherence_. 2018;12:1261-1271. Published 2018 Jul 19. doi:10.2147/PPA.S145646

04. McCarron TL, Noseworthy T, Moffat K, et al. Understanding the motivations of patients: A co-designed project to understand the factors behind patient engagement. _Health Expect_. 2019;22(4):709-720. doi:10.1111/hex.12942

05. Alkhatib AJ, Alzoubi A, Alharoun M, et al. The Impact of Patient Engagement on Healthcare: A Systematic Review of Unveiling the Benefits of Patient Engagement in Healthcare. _Multicriteria Algorithms with Applications_. 2024;3:23-31. doi: 10.61356/j.mawa.2024.311661

06. [https://www.openhealthgroup.com/news/23-07-2024/the-science-behind-patient-stories/](https://www.openhealthgroup.com/news/23-07-2024/the-science-behind-patient-stories/)

07. Ferguson MC, McNicol E, Kleykamp BA, et al. Perspectives on Participation in Clinical Trials Among Individuals With Pain, Depression, and/or Anxiety: An ACTTION Scoping Review. _J Pain_. 2023;24(1):24-37. doi:10.1016/j.jpain.2022.09.001

08. Ghebreyesus TA. Using behavioural science for better health. _Bull World Health Organ_. 2021;99(11):755. doi:10.2471/BLT.21.287387

09. Fukami T. Patient engagement with psychological safety. _Dialogues Health_. 2023;3:100153. Published 2023 Sep 17. doi:10.1016/j.dialog.2023.100153

10. [National Institute for Health and Care Excellence shared decision making guideline](https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/shared-decision-making) (2021)

11. [The Power of Positive Reinforcement: Using Behavioral Techniques to Enhance Patient Engagement](https://www.ceuoutlet.com/blog/the-power-of-positive-reinforcement-using-behavioral-techniques-to-enhance-patient-engagement) (2023)

12. Deeb LC, Parkes JL, Pardo S, et al. Performance of the DIDGET blood glucose monitoring system in children, teens, and young adults. _J Diabetes Sci Technol_. 2011;5(5):1157-1163. Published 2011 Sep 1. doi:10.1177/193229681100500518


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Gap Analyses in Healthcare
# The power of gap analyses in driving medical discovery

Despite the wealth of information being generated and integrated into our rapidly transforming clinical healthcare landscape, significant unmet needs and research gaps remain. (1) Gaps in scientific knowledge and clinical trial data are particularly problematic in rare diseases, with over 90% lacking a clinically approved therapeutic. (2)It is valuable to identify these research gaps to guide future clinical trials, study endpoints, and policymaking, ultimately improving health outcomes for people living with disease. (1)

A gap analysis of scientific literature is a systematic method used to identify insufficient areas in existing research within a particular therapy area. Researchers conduct these analyses to recognise inconsistencies between study findings, identify uncertainties—such as the effects of treatments on different or underserved patient populations—and highlight areas for improvement in healthcare research. Moreover, gap analyses can help determine how effectively ongoing research aligns with current clinical practice needs. (3)

For example, it has been identified that only one-third of the research evidence informing primary care guidelines is routinely adhered to. To address this issue, Lau and colleagues conducted a systematic literature review to summarise the barriers and facilitators to understand why these guidelines were overlooked and guide greater adherence. By analysing this gap, they developed recommendations to support the implementation of guidelines in clinical practice and policy, serving as a real-world example of how research gap analyses can drive meaningful changes in clinical practice for the benefit of patients. (4)

While various methodologies exist to determine research gaps in healthcare, there is no universally accepted standard or best practice. Nevertheless, previous studies describe conducting an initial comprehensive literature review by searching relevant databases such as PubMed to define key inclusion and exclusion criteria and to establish the number and scope of existing publications. In turn, it is common to perform qualitative and quantitative analyses, such as thematic and frequency analysis, to categorise the findings and identify gaps in the literature. Finally, the relevance and significance of identified gaps should be evaluated to inform future research priorities. (5)

Alongside technological advancements, the role of big data and artificial intelligence is growing, reducing the time and resources needed to identify research gaps. Leveraging tools such as machine learning to analyse large datasets can automate literature gap analyses, driving discovery in the healthcare industry to deliver optimal patient care. (6) Moreover, the benefit of wider stakeholder engagement is becoming increasingly recognised in gap analyses—involving patients, advocates, clinicians, researchers, funders, and policymakers in the process helps to ensure that identified gaps and future research objectives are actionable and relevant for all. (5,7)

To ensure the results of a gap analysis are translated into actionable research strategies, such as clinical trials or policy initiatives, key findings must be shared with the wider pharmaceutical and scientific community through academic journals, white papers, or presentations. Further, reports or publications should be tailored to different audiences to ensure that recommendations for action are clear, making the next steps more accessible. (5)

At Synthesis, we apply our expert medical writing skills to run scoping literature searches and identify critical research gaps. Through publications that disseminate and elevate the findings of gap analyses, we aim to guide future clinical trials and inform policy, fostering systematic change that benefits diverse stakeholders. Contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to explore how we can help you perform comprehensive gap analyses and effectively share outputs across the industry. Together, we can standardise the adoption of gap analysis in healthcare research, driving meaningful progress in medical discovery for all.

* * *

**References**

1. Naqvi WM, Gabr M, Arora SP, Mishra GV, Pashine AA, Quazi Syed Z. Bridging, Mapping, and Addressing Research Gaps in Health Sciences: The Naqvi-Gabr Research Gap Framework. _Cureus_. 2024;16(3):e55827. Published 2024 Mar 8. doi:10.7759/cureus.55827

2. Austin CP, Cutillo CM, Lau LPL, et al. Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. _Clin Transl Sci_. 2018;11(1):21-27. doi:10.1111/cts.12500

3. Gillespie CS, Fung KW, Alam AM, et al. How does research activity align with research need in chronic subdural haematoma: a gap analysis of systematic reviews with end-user selected knowledge gaps. _Acta Neurochir (Wien)_. 2023;165(7):1975-1986. doi:10.1007/s00701-023-05618-2

4. Lau R, Stevenson F, Ong BN, et al. Achieving change in primary care--causes of the evidence to practice gap: systematic reviews of reviews. Implement Sci. 2016;11:40. Published 2016 Mar 22. doi:10.1186/s13012-016-0396-4

5. Nyanchoka L, Tudur-Smith C, Thu VN, Iversen V, Tricco AC, Porcher R. A scoping review describes methods used to identify, prioritize and display gaps in health research. _J Clin Epidemiol_. 2019;109:99-110. doi:10.1016/j.jclinepi.2019.01.005

6. Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. _BMC Med Educ_. 2023;23(1):689. Published 2023 Sep 22. doi:10.1186/s12909-023-04698-z

7. Martinez J, Wong C, Piersol CV, Bieber DC, Perry BL, Leland NE. Stakeholder engagement in research: a scoping review of current evaluation methods. _J Comp Eff Res_. 2019;8(15):1327-1341. doi:10.2217/cer-2019-0047


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient-Centered Care Education
# Educating healthcare professionals for patient-centred care

Healthcare professionals (HCPs) are at the forefront of patient partnerships—they directly interact with patients to guide and inform their healthcare decisions.

This raises the critical question: As an industry, are we supporting HCPs in delivering patients the best standard of care?

## **Scoping the current education landscape**

HCP training typically focuses on the clinical and theoretical knowledge underlying medical conditions and their corresponding treatment strategies. While this information is critical for delivering high-quality care, structured training on how to effectively interact and connect with individuals living with disease and take a shared decision-making approach is often overlooked. (1) A key barrier to meaningful patient care is inadequate HCP education around supporting engagement initiatives. (2)With a lack of targeted training on how to involve patients in clinical trials, patient advocacy groups, or ambassador programmes, many patients remain unaware of the diverse routes they can take to actively engage in their care beyond their appointment. Previous research has demonstrated the association between poor patient-provider communication and the quality of patient care. (3)In extreme cases, substandard communication skills can lead to misunderstandings in these two-way interactions, increasing the risk of life-threatening errors, including misdiagnosis or ineffective treatment plans. (4)This highlights a critical gap in current HCP education programmes in building open, professional relationships with patients that foster mutual understanding. Beyond this, when continuous professional development initiatives are established, prior research suggests there is often a disconnect between course content and its translation into patient-focused care due to barriers such as time constraints and resourcing. (5)

Despite these shortfalls, there is increasing recognition in the literature of the need to integrate patient interaction into HCP training. For example, in a literature-based study, Kwame and Petrucka (2021) emphasise the importance of continuous professional development for advancing active listening, among other communication skills, such as compassion and approaching topics with sensitivity. (3)Another study highlighted the value of hospital-based person-centred communication training on HCPs’ self-efficacy. (6) Further, an integral part of HCP education involves exposure to clinical settings, with medical school curricula involving structured clinical placements. Therefore, although trainees may not receive fundamental patient-focused training, they have the opportunity to interact with actual patients in real-world settings, shadowing practitioners in their daily roles. (7)

## **Advancing HCP education beyond medical school**

So, what do HCPs need to enhance person-focused care on a day-to-day basis?

Patients possess valuable knowledge—they understand the lived experience of the disease itself. Therefore, HCPs should consider patients as ‘experts’ of their condition and leverage their insights to improve the delivery of human-centred care. The European Society for Medical Oncology (ESMO) exemplifies this by offering patients the opportunity to attend meetings to share their concerns and ideals, thereby contributing to the alignment of cancer care development with patient needs. (8) With this in mind, building patients’ lived experiences into medical education presents a strong, actionable solution for humanising healthcare.

![](https://a.storyblok.com/f/166410/8182x5455/6133a05f50/listening-patients.jpg)A holistic approach to care is one key skill that has a demonstrated positive impact on patient outcomes. To support physicians' understanding of complex patient needs, incorporating patients’ overall wellbeing—emotional, social, and physical—and the impact of disease on daily life into educational programmes offers one strategy to enhance patient satisfaction. (9)

Other studies highlight the link between effective, two-way communication strategies—such as active listening and collaborative discussion—and positive health-related outcomes, including enhanced quality of life. For example, physicians who adopt collaborative communication by actively listening and working alongside patients to build trust and mutual respect are associated with greater treatment adherence among those living with psychiatric conditions. (10)This evidence further supports the case for HCP education that extends beyond medical science and towards patient-centred care.

Although initiatives that encompass the power of patient voices have gained momentum in recent years, such as Rita Charon’s movement around narrative medicine, which inspires the medical community to espouse patient narratives, there is an ongoing need for standardised continuous professional development programmes and practical guidance to help HCPs learn from patients. (11)

* * *

To design educational programmes that truly enhance the patient care experience, pharma must work alongside patient advocacy groups and individuals who have lived through the disease firsthand. At Synthesis, we recognise the power of a collaborative approach—bringing patients, HCPs, and researchers together to humanise healthcare and education. Rethinking HCP training to incorporate real-life experiences is a valuable step toward a care system tailored to patients’ true needs. Contact us at info@synthesishealth.co.uk to learn how we can support policy initiatives that drive patient-centred healthcare and raise awareness of your efforts to engage with patient communities.

* * *

**References**

01. Rajashree K. Training programs in communication skills for health care professionals and volunteers. _Indian J Palliat Care_. 2011;17(Suppl):S12-S13. doi:10.4103/0973-1075.76232

02. Sarkhosh S, Abdi Z, Ravaghi H. Engaging patients in patient safety: a qualitative study examining healthcare managers and providers' perspectives. _BMC Nurs_. 2022;21(1):374. Published 2022 Dec 29. doi:10.1186/s12912-022-01152-1

03. Kwame A, Petrucka PM. A literature-based study of patient-centered care and communication in nurse-patient interactions: barriers, facilitators, and the way forward. _BMC Nurs_. 2021;20(1):158. Published 2021 Sep 3. doi:10.1186/s12912-021-00684-2

04. Howick J, Bennett-Weston A, Solomon J, Nockels K, Bostock J, Keshtkar L. How does communication affect patient safety? Protocol for a systematic review and logic model. _BMJ Open_. 2024;14(5):e085312. Published 2024 May 27. doi:10.1136/bmjopen-2024-085312

05. Al-Omary H, Soltani A, Stewart D, Nazar Z. Implementing learning into practice from continuous professional development activities: a scoping review of health professionals' views and experiences. _BMC Med Educ_. 2024;24(1):1031. Published 2024 Sep 20. doi:10.1186/s12909-024-06016-7

06. Wolderslund M, Kofoed PE, Ammentorp J. The effectiveness of a person-centred communication skills training programme for the health care professionals of a large hospital in Denmark. _Patient Educ Couns_. 2021;104(6):1423-1430. doi:10.1016/j.pec.2020.11.018

07. [https://www.healthcareers.nhs.uk/explore-roles/doctors/medical-school/clinical-placements-medical-students](https://www.healthcareers.nhs.uk/explore-roles/doctors/medical-school/clinical-placements-medical-students)

08. [https://www.esmo.org/policy/patient-advocates-working-group](https://www.esmo.org/policy/patient-advocates-working-group)

09. Jasemi M, Valizadeh L, Zamanzadeh V, Keogh B. A Concept Analysis of Holistic Care by Hybrid Model. _Indian J Palliat Care_. 2017;23(1):71-80. doi:10.4103/0973-1075.197960

10. Jenstad LM, Howe T, Breau G, et al. Communication between healthcare providers and communicatively-vulnerable patients with associated health outcomes: A scoping review of knowledge syntheses. _Patient Educ Couns_. 2024;119:108040. doi:10.1016/j.pec.2023.108040

11. [https://nihrecord.nih.gov/2019/11/01/charon-espouses-power-narrative-medicine](https://nihrecord.nih.gov/2019/11/01/charon-espouses-power-narrative-medicine)


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Improving Patient Access
1 May 2025

# Improving direct patient access to clinical trials

Clinical trials are pivotal in the drug discovery and development cycle. They enhance patient access to safe and effective treatments to improve their overall quality of life and, in some cases, slow disease progression by interfering with faulty mechanisms. Hence, a key barrier in healthcare is the low patient recruitment (and high dropout) rates in clinical settings.

### **Who is responsible for recruiting patients?**

Despite the importance of patient involvement, it is unclear who is responsible for recruiting patients in clinical trials. In accordance with the Declaration of Helsinki (a set of ethical guidelines for researchers to follow when conducting medical research involving human participants), this role should lie with healthcare professionals (HCPs) to ensure that patients are adequately informed about the potential benefits and risks associated with clinical trials. (1) While HCPs are critical in informing patients about trials and facilitating recruitment, seen as trusted sources in the eyes of patients, they are often under significant time constraints and do not receive compensation for these services. As a result, evidence indicates that HCPs refer an inadequate number of patients to clinical trials annually to ensure robust patient cohorts. (2)

Patient advocacy groups (PAGs) (organisations that support individuals living with disease by providing information, resources, and a voice for patients) offer an alternative route to educate patients about relevant clinical trials. This has been effectively demonstrated by the PACER programme in India, comprising online courses, workshops, and focus group discussions. As a result, participants' awareness of clinical research increased, addressing misconceptions and building trust. (3) However, there is a lack of standardised protocols for involving PAGs and other patient organisations in clinical trial awareness and accessibility.

### **Can patients recruit themselves?**

Existing platforms for patients to find suitable clinical trials are often limited, with many offering complex or inaccessible information. As patient-centred care grows, there is a demand for better tools that empower patients to take control of their health and seek out clinical trials directly.

Patients can search online databases to identify clinical trials that match their preferences and needs. ClinicalTrials.gov is a well-known platform where patients can refine their search using filters such as disease and location. ClinicalTrials.gov provides a comprehensive list of trials spanning all therapy domains, treatments, and locations worldwide, as well as up-to-date and transparent information to help patients make informed decisions. Despite this, ClinicalTrials.gov is designed for researchers, which makes it less accessible for patients. For example, when searching for breast cancer studies in Edinburgh, the first trial that appears is ‘Axillary Management in Breast Cancer Patients with Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy (ATNEC)’. This language is highly technical and can be overwhelming, requiring considerable effort from non-experts to understand. Further, this database primarily serves as a self-navigating tool (e.g., there is no live chat function to assist patients) for trial enrollment. (4)

Fortunately, user-friendly alternatives are available to support patients embarking on their clinical trial journey. [Antidote](https://www.antidote.me/) is one example of a patient-focused trial search platform, asking patients simple questions to determine appropriate options, providing easy-to-understand trial descriptions, and offering a messaging service. (5) [Ancora.ai](http://ancora.ai/) offers another digital clinical trial navigation tool for patients, connecting people living with cancer to novel therapeutics. (6) Similarly, many PAG websites offer personalised clinical trial matching tools, such as [BreatCancerTrials.org](https://www.breastcancertrials.org/BCTIncludes/WhyParticipate/WhyClinicalTrialsAreImportant.html), bridging patient-centred care and clinical research with artificial intelligence (AI). (7)

![](https://a.storyblok.com/f/166410/5184x3456/bfa5d1a7fd/doctor-typing.jpg)

### **How can we improve direct patient access to trials?**

Although some patient-friendly databases and AI-driven trial matching have been established, industry professionals must leverage these platforms and direct patients to them to improve clinical trial access and participation.

Ansah and colleagues (2024) demonstrate the value of the “Speaking Book”—an interactive, audio-visual tool that educates patients about clinical trial participation in their native language—for improving patient understanding and awareness of clinical trials, particularly in underserved communities with low literacy levels. (8) Likewise, with guidance from a patient navigator, bilingual educational videos involving cancer patients sharing their experiences have been shown to increase clinical trial participation among underrepresented populations. (9) Leveraging these strategies ensures equitable access to clinical trials and fosters a diverse and inclusive clinical landscape.

Digital outreach—circulating upcoming clinical trials on social media—has also proven effective in increasing patient awareness and access to clinical trials. One example is a 2019 digital public awareness campaign that used targeted Facebook adverts to promote awareness of the [ResearchMatch Trials Today clinical trial search tool](https://www.trialstoday.org/?) among patients in the United States. This resulted in higher engagement rates at a low cost. (10)

With the growing digital space, disseminating lay materials across diverse patient populations is becoming easier. This shift is critical to empower patients with the resources and knowledge they need to actively engage in their care. At Syntheis, we recognise the importance of user-friendly platforms that help patients understand the true experience of participating in a clinical trial and simplify the navigation process. Contact us at info@synthesishealth.co.uk to learn how we can help you strengthen patient partnerships and promote awareness of clinical research engagement strategies to improve patient recruitment and retention.

* * *

**References**

01. [https://www.wma.net/policies-post/wma-declaration-of-helsinki/](https://www.wma.net/policies-post/wma-declaration-of-helsinki/)

02. Getz KA. Examining and Enabling the Role of Health Care Providers as Patient Engagement Facilitators in Clinical Trials. _Clin Ther_. 2017;39(11):2203-2213. doi:10.1016/j.clinthera.2017.09.014

03. Bagai P, Sharma P, Ansari A, et al. Patient Advocates for Clinical Research (PACER): A Step Toward Ethical, Relevant, and Truly Participatory Clinical Research in India. _Cureus_. 2024;16(4):e58454. Published 2024 Apr 17. doi:10.7759/cureus.58454

04. [https://clinicaltrials.gov/](https://clinicaltrials.gov/)

05. [https://www.antidote.me/](https://www.antidote.me/)

06. [http://Ancora.ai](http://ancora.ai/)

07. [https://www.breastcancertrials.org/BCTIncludes/WhyParticipate/WhyClinicalTrialsAreImportant.html](https://www.breastcancertrials.org/BCTIncludes/WhyParticipate/WhyClinicalTrialsAreImportant.html)

08. Ansah P, Parmar B, Onyango D, et al. Prospective, Multicenter Study to Assess the Effect of the Speaking Book on Patients' Understanding of Clinical Research Knowledge: The SOUND Study. _Blood._ 2024;144 (Supplement 1):2441. [doi:10.1182/blood-2024-206983](https://doi.org/10.1182/blood-2024-206983)

09. Chalela P,  Cortez V,  Flores A, et al. Abstract A064: My Choices: A multilevel, multicomponent intervention to improve informed decision-making about clinical trial participation among cancer patients. _Cancer Epidemiol Biomarkers Prev._ 2023;32 (12\_Supplement):A064. [doi:10.1158/1538-7755.DISP23-A064](https://doi.org/10.1158/1538-7755.DISP23-A064)

10. Jerome RN, Dunkel L, Kennedy N, et al. To end disease tomorrow, begin with trials today: Digital strategies for increased awareness of a clinical trials finder. _J Clin Transl Sci_. 2019;3(4):190-198. Published 2019 Aug 20. doi:10.1017/cts.2019.404


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Exit Interviews in Trials
# Understanding patient experiences in clinical trials: Should exit interviews be considered essential?

Drug development refers to the process of bringing a new medicine to market to improve patients’ lives—but how often do we ask patients themselves about their overall treatment experiences? While exit interviews are becoming more common, they remain far from a universal standard in clinical practice.

## **What are exit interviews, and what do they aim to achieve?**

Exit interviews involve in-depth discussions with patients—and sometimes their caregivers—to gather qualitative feedback about their treatment experiences, perceptions of efficacy, and overall quality of life in clinical trials. (1)

As patient-centred research and regulatory decision-making gain prominence in the healthcare industry, exit interviews can empower patients and shape the drug development lifecycle to align with their true needs and preferences. Exit interviews advance patient-centric research by: (2,3)

1. Capturing patients’ perspectives on their treatment journeys, assessing whether changes in their disease experience are meaningful

2. Identifying the safety profile and evaluating the benefits and risks of novel interventions, providing opportunities for further advancement

3. Supporting the development and interpretation of patient-reported outcomes (PROs)

4. Informing future trial designs and endpoint selection to better address patient needs


## **How and when are exit interviews conducted?**

Exit interviews can be ‘embedded’ within clinical trials, conducted either as a one-off or at various points throughout the trial. Alternatively, patient insights can be gathered through associated interview studies, where participants enrol in exit interviews after completing the trial. (1)

Some trials collect qualitative data through focus group discussions to foster participant interaction and gather diverse insights, while others adopt a more personal approach with one-on-one interviews. Focus group discussions typically use a discussion guide with open-ended questions, and one-on-one interviews follow a semi-structured guide with predetermined questions. Both approaches allow the researcher to shape the conversation around specific topics and probe further when necessary, ensuring qualitative feedback objectives are met. (4,5) Additionally, patient-completed questionnaires may be included to complement data collected from qualitative interviews. For example, in one study, patients who received tirzepatide for type 2 diabetes completed the EQ-5D-5L questionnaire after an exit interview to assess their overall health status. This allowed the sponsor to identify the health domains most affecting patients with type 2 diabetes, with pain/discomfort and mobility being the most commonly reported challenges. (2)

![](https://a.storyblok.com/f/166410/5184x3456/2b6383331f/questionnaire.jpg)A critical aspect of the exit interview methodology is interviewer training. The interviewer must be familiar with the discussion guide to ensure the conversation flows smoothly and covers all key topics. (2) Furthermore, the relationship between the interviewer and interviewee should be considered; interviewers should always be third parties to minimise potential bias.

Although interviewers undergo thorough training, they are not responsible for collecting all the participants' feedback during the interview. Exit interviews are audio-recorded (with the participants’ informed consent) and transcribed verbatim. The researchers then code the transcriptions to categorise the data into common themes, making it easier to analyse. (2)

## **How can exit interviews benefit both sponsors and patients?**

The rich, qualitative information collected during exit interviews can provide valuable benefits for multiple stakeholders, including sponsors and patients.

By exploring meaningful changes in patients’ disease and treatment effects extending beyond clinical indicators, sponsors can:6

- Provide real-world evidence to shape regulatory submissions

- Guide marketing strategies

- Inform the design of future studies

- Support the development and approval of publications

- Refine PRO endpoints


One example of the value of exit interviews in identifying novel PRO endpoints was described by Matza and colleagues (2022). In qualitative interviews following treatment, patients with type 2 diabetes highlighted the significant emotional impact of improved glycemic control, body weight, and energy. These findings suggest that assessing the emotional impact of type 2 diabetes treatment could be a valuable PRO measure in future clinical trials. (2)

Similarly, participating in exit interviews can give patients a sense of empowerment by allowing them to contribute to research that may advance the standard of care for others and share their experiences—both positive and negative.

These multi-stakeholder benefits are especially valuable in the rare disease space due to the underrepresentation of these conditions. (6)

## **How can we maximise stakeholder outcomes from exit interviews?**

By communicating diverse, qualitative patient experiences to patients and the broader scientific community, we can enhance transparency and foster trust across stakeholder groups to strengthen these collaborations. Broader dissemination is valuable to encourage the adoption of best practices in patient-centric trial design and demonstrate how patient feedback shapes treatment development.

At Synthesis, we leverage our medical writing expertise to amplify the power of patient voices in the clinical landscape. By developing publications that disseminate and elevate the findings of exit interviews, we aim to improve patient experiences and enhance clinical trial outcomes. Contact us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) to discover how we can help you integrate exit interviews into a comprehensive patient engagement strategy. Together, we can standardise the role of exit interviews in clinical settings and drive progress in the drug development process for all stakeholders.

* * *

**References**

1. Addressing the Challenges of Conducting Qualitative Interviews within Clinical Trials [https://www.evidera.com/wp-content/uploads/2024/05/Addressing-the-Challenge-Qualitative-Interviews.pdf](https://www.evidera.com/wp-content/uploads/2024/05/Addressing-the-Challenge-Qualitative-Interviews.pdf)

2. Matza LS, Stewart KD, Landó LF, Patel H, Boye KS. Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes. _Patient_. 2022;15(3):367-377. doi:10.1007/s40271-022-00578-8

3. Michel AS, Kamudoni P, Marrel A, et al. Integrating qualitative interviews in drug development and the use of qualitative evidence in product labelling and health technology assessments: a review. _Front Med (Lausanne)_. 2023;10:1197529. Published 2023 Jun 20. doi:10.3389/fmed.2023.1197529

4. Khalife J, Ekman B, Ammar W, et al. Exploring patient perspectives: A qualitative inquiry into healthcare perceptions, experiences and satisfaction in Lebanon. _PLoS One_. 2023;18(8):e0280665. Published 2023 Aug 17. doi:10.1371/journal.pone.0280665

5. Chladek M, Burbridge C, Gibbons E, Willgoss T, Smith J, Clinch S. Qualitative Exploration in Exit Interviews of Changes Observed in Clinical Trials for Individuals with Autism Spectrum Disorder Without Intellectual Disability. _Patient Relat Outcome Meas_. 2023;14:313-335. Published 2023 Nov 21. doi:10.2147/PROM.S385682

6. DiBenedetti DB, Brown T, Romano C, et al. Conducting Patient Interviews Within a Clinical Trial Setting \[Internet\]. Research Triangle Park (NC): RTI Press; 2018 Aug. Available from: [https://www.ncbi.nlm.nih.gov/books/NBK542736/doi: 10.3768/rtipress.2018.op.0054.1808](https://www.ncbi.nlm.nih.gov/books/NBK542736/doi)


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Manuscript Rejection Reasons
# 8 reasons why journals may reject your manuscripts

Before a medical manuscript even reaches a journal’s Editor-in-Chief or is selected for peer review, it is subjected to intense scrutiny, which, more often than not, results in rejection. ​​Rejection rates of top-tier journals typically vary between 80-85%, but for some journals, rejection has been reported to be as high as 90-95%. (1)

Example acceptance rates of high-ranking scientific journals:

- [The British Medical Journal (BMJ)](https://www.bmj.com/about-bmj/publishing-model) accepts about **7%** of all the 7,000-8,000 manuscripts submitted each year, but many of these are not research articles. Only **4%** of research articles are accepted.

- [Nature](https://www.nature.com/nature/for-authors/editorial-criteria-and-processes)’s most recently publicised submission acceptance rate was **7.6%** in 2017.

- [The New England Journal Medicine (NEJM)](https://www.nejm.org/about-nejm/about-nejm) and [The Lancet](https://www.journalguide.com/journals/the-lancet) both have an acceptance rate of around **5%.**

- [The Journal of the American Medical Association (JAMA)](https://jamanetwork.com/journals/jama/pages/for-authors)’s acceptance rate is **11%** of the 7,000+ major manuscripts it receives annually, and only **4%** of the 4,400+ research papers received.


![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%271090%27%20height=%271001%27/%3e)![Stats on journal publication rates](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1090x1001%2F20f6855611%2Fresearch-journal-pub-stats.png&w=3840&q=90)

> Rejection rates of top-tier journals typically vary between 80-85%, but for some journals, rejection has been reported to be as high as 90-95%

Naturally, medical research must meet a set of standards to be deemed worthy of publishing. For example, research must be supported by a strong hypothesis, flawless methodology and accurate, complete data. However, even those papers whose research and data meet these standards may still be rejected following editorial review.

So, what are the key reasons a manuscript may be rejected? (2-4)

1. It does not comply with the target journal’s requirements and instructions to authors or lacks the necessary supporting documents.

2. It contains information that is suspected to be plagiarised or under review by another journal.

3. It is incomplete - for example, it may lack key elements such as title, keywords, references, tables and figures etc.

4. The tables or figures are unreadable - for example, figures are of low resolution or tables are too complex.

5. References are incomplete, out-of-date, or not presented as per the journal style.

6. It is poorly written

   - The spelling or grammar is sub-standard.

   - There is an absence of clarity, structure, or content organisation.

   - Arguments are illogical, unstructured or invalid.

   - The conclusions fail to acknowledge the published literature.

   - The results do not provide an answer to the question(s) posed in the aims and objectives.
7. It is out of scope for the journal and its readership - i.e., it does not fall within a target journal’s aims and scope (the objective or purpose of what the journal is trying to achieve and how the journal aims to accomplish it).

8. It does not contribute any new or interesting knowledge to the area concerned.


> Medical writers reduce the risk and impact of inexperience regarding publications practise

To avoid the many pitfalls that can lead to a manuscript being rejected, medical writers provide invaluable support in developing well-organised, well-written, high-quality manuscripts. As well as providing an unbiased scientific perspective, medical writers improve the quality of an author’s writing, minimise the time, cost and frustration required to deliver manuscripts, and reduce the risk and impact of inexperience regarding publications practise.

* * *

At Synthesis _,_ we offer specialised manuscript writing support, working with authors to effectively organise and communicate their research or recommendations and ensure the article presents new and interesting information that attracts and holds the attention of its readership. Moreover, we work with clients to develop publication plans and identify appropriate target journals or congresses to ensure the paper’s messages are suitable for the intended audience.

Whether you’re looking for ad-hoc or long-term publications support, [contact us](https://synthesishealth.co.uk/work-with-us) to learn more about how we can work together to maximise the reach and clarity of your content.

* * *

References:

1. Khadilkar SS. Rejection Blues: Why Do Research Papers Get Rejected? _J Obstet Gynaecol India_. 2018;68(4):239–241. doi:10.1007/s13224-018-1153-1

2. Thrower P. Eight reasons I rejected your article. _Elsevier Connect._ 2012

3. Dantas-Torres F. Top 10 reasons your manuscript may be rejected without review. _Parasit Vectors._ 2022;15(418). [doi.org/10.1186/s13071-022-05543-w](http://doi.org/10.1186/s13071-022-05543-w)

4. Pierson D. J. The top 10 reasons why manuscripts are not accepted for publication. _Respir Care_. 2004;49(10):1246–1252


This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Privacy Policy Overview
# Privacy Policy

Last updated: March 24th, 2025

This Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Service and tells You about Your privacy rights and how the law protects You.

We use Your Personal data to provide and improve the Service. By using the Service, You agree to the collection and use of information in accordance with this Privacy Policy.

## Interpretation and Definitions

### Interpretation

The words of which the initial letter is capitalized have meanings defined under the following conditions. The following definitions shall have the same meaning regardless of whether they appear in singular or in plural.

### Definitions

For the purposes of this Privacy Policy:

- Account means a unique account created for You to access our Service or parts of our Service.

- Affiliate means an entity that controls, is controlled by or is under control with a party, where "control" means ownership of 50% or more of the shares, equity interest or other securities entitled to vote for election of directors or other managing authority.

- Company (referred to as either "the Company", "We", "Us" or "Our" in this Agreement) refers to Synthesis FZE, 25.B Maktabi, Floor 18, Sheikh Rashid Tower, Dubai World Trade Centre, Dubai, United Arab Emirates. For the purpose of the GDPR, the Company is the Data Controller.

- Cookies are small files that are placed on Your computer, mobile device or any other device by a website, containing the details of Your browsing on that website among its many uses.

- Country refers to: United Arab Emirates

- Data Controller , for the purposes of the GDPR (General Data Protection Regulation), refers to the Company as the legal person which alone or jointly with others determines the purposes and means of the processing of Personal Data.

- Device means any device that can access the Service such as a computer, a cellphone or a digital tablet.

- GDPR refers to EU General Data Protection Regulation.

- Personal Data is any information that relates to an identified or identifiable individual. For the purposes of GDPR, Personal Data means any information relating to You, such as a name, an identification number, location data, online identifier or one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity.

- Service refers to the Website.

- Service Provider means any natural or legal person who processes the data on behalf of the Company. It refers to third-party companies or individuals employed by the Company to facilitate the Service, to provid the Service on behalf of the Company, to perform services related to the Service or to assist the Company in analyzing how the Service is used. For the purpose of the GDPR, Service Providers are considered Data Processors.

- Usage Data refers to data collected automatically, either generated by the use of the Service or from the Service infrastructure itself (for example, the duration of a page visit).

- Website refers to Synthesis Health, accessible from [https://synthesishealth.co.uk](https://synthesishealth.co.uk/)

- You means the individual accessing or using the Service, or the company, or other legal entity on behalf of which such individual is accessing or using the Service, as applicable.

- Under GDPR, You can be referred to as the Data Subject or as the User as you are the individual using the Service.


## Collecting and Using Your Personal Data

### Types of Data Collected

#### Personal Data

While using Our Service, We may ask You to provide Us with certain personally identifiable information that can be used to contact or identify You. Personally identifiable information may include, but is not limited to:

- Email address

- Usage Data


#### Usage Data

Usage Data is collected automatically when using the Service. Usage Data may include information such as Your Device's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Service that You visit, the time and date of Your visit, the time spent on those pages, unique device identifiers and other diagnostic data. When You access the Service by or through a mobile device, We may collect certain information automatically, including, but not limited to, the type of mobile device You use, Your mobile device unique ID, the IP address of Your mobile device, Your mobile operating system, the type of mobile Internet browser You use, unique device identifiers and other diagnostic data. We may also collect information that Your browser sends whenever You visit our Service or when You access the Service by or through a mobile device.

### Tracking Technologies and Cookies

We use Cookies and similar tracking technologies to track the activity on Our Service and store certain information. Tracking technologies used are beacons, tags, and scripts to collect and track information and to improve and analyze Our Service. The technologies We use may include:

- Cookies or Browser Cookies. A cookie is a small file placed on Your Device. You can instruct Your browser to refuse all Cookies or to indicate when a Cookie is being sent. However, if You do not accept Cookies, You may not be able to use some parts of our Service. Unless you have adjusted Your browser setting so that it will refuse Cookies, our Service may use Cookies.

- Web Beacons. Certain sections of our Service and our emails may contain small electronic files known as web beacons (also referred to as clear gifs, pixel tags, and single-pixel gifs) that permit the Company, for example, to count users who have visited those pages or opened an email and for other related website statistics (for example, recording the popularity of a certain section and verifying system and server integrity).

- Cookies can be "Persistent" or "Session" Cookies. Persistent Cookies remain on Your personal computer or mobile device when You go offline, while Session Cookies are deleted as soon as You close Your web browser. You can learn more about cookies online.


We use both Session and Persistent Cookies for the purposes set out below:

* * *

**Necessary / Essential Cookies**

**Type:** Session Cookies

**Administered by:** Us

**Purpose:** These Cookies are essential to provide You with services available through the Website and to enable You to use some of its features. They help to authenticate users and prevent fraudulent use of user accounts. Without these Cookies, the services that You have asked for cannot be provided, and We only use these Cookies to provide You with those services.

* * *

**Cookies Policy / Notice Acceptance Cookies**

**Type:** Persistent Cookies

**Administered by:** Us

**Purpose:** These Cookies identify if users have accepted the use of cookies on the Website.

* * *

**Functionality Cookies**

**Type:** Persistent Cookies

**Administered by:** Us

**Purpose:** These Cookies allow us to remember choices You make when You use the Website, such as remembering your login details or language preference. The purpose of these Cookies is to provide You with a more personal experience and to avoid You having to re-enter your preferences every time You use the Website.

* * *

For more information about the cookies we use and your choices regarding cookies, please visit our [Cookies Policy](https://synthesishealth.co.uk/cookie-policy) or the Cookies section of our Privacy Policy.

### Use of Your Personal Data

The Company may use Personal Data for the following purposes:

- To provide and maintain our Service , including to monitor the usage of our Service.

- To manage Your Account: to manage Your registration as a user of the Service. The Personal Data You provide can give You access to different functionalities of the Service that are available to You as a registered user.

- For the performance of a contract: the development, compliance and undertaking of the purchase contract for the products, items or services

  - You have purchased or of any other contract with Us through the Service.
- To contact You: To contact You by email, telephone calls, SMS, or other equivalent forms of electronic communication, such as a mobile application's push notifications regarding updates or informative communications related to the functionalities, products or contracted services, including the security updates, when necessary or reasonable for their implementation.

- To provide You with news, special offers and general information about other goods, services and events which we offer that are similar to those that you have already purchased or enquired about unless You have opted not to receive such information.

- To manage Your requests: To attend and manage Your requests to Us.

- For business transfers: We may use Your information to evaluate or conduct a merger, divestiture, restructuring, reorganization, dissolution, or other sale or transfer of some or all of Our assets, whether as a going concern or as part of bankruptcy, liquidation, or similar proceeding, in which Personal Data held by Us about our Service users is among the assets transferred.

- For other purposes : We may use Your information for other purposes, such as data analysis, identifying usage trends, determining the effectiveness of our promotional campaigns and to evaluate and improve our Service, products, services, marketing and your experience.


We may share Your personal information in the following situations:

- With Service Providers: We may share Your personal information with Service Providers to monitor and analyze the use of our Service, to contact You.

- For business transfers: We may share or transfer Your personal information in connection with, or during negotiations of, any merger, sale of Company assets, financing, or acquisition of all or a portion of Our business to another company.

- With Your consent : We may disclose Your personal information for any other purpose with Your consent.


### Retention of Your Personal Data

The Company will retain Your Personal Data only for as long as is necessary for the purposes set out in this Privacy Policy. We will retain and use Your Personal Data to the extent necessary to comply with our legal obligations (for example, if we are required to retain your data to comply with applicable laws), resolve disputes, and enforce our legal agreements and policies.

The Company will also retain Usage Data for internal analysis purposes. Usage Data is generally retained for a shorter period of time, except when this data is used to strengthen the security or to improve the functionality of Our Service, or We are legally obligated to retain this data for longer time periods.

### Transfer of Your Personal Data

Your information, including Personal Data, is processed at the Company's operating offices and in any other places where the parties involved in the processing are located. It means that this information may be transferred to — and maintained on — computers located outside of Your state, province, country or other governmental jurisdiction where the data protection laws may differ than those from Your jurisdiction.

Your consent to this Privacy Policy followed by Your submission of such information represents Your agreement to that transfer.

The Company will take all steps reasonably necessary to ensure that Your data is treated securely and in accordance with this Privacy Policy and no transfer of Your Personal Data will take place to an organization or a country unless there are adequate controls in place including the security of Your data and other personal information.

### Delete Your Personal Data

You have the right to delete or request that We assist in deleting the Personal Data that We have collected about You.

Our Service may give You the ability to delete certain information about You from within the Service. You may update, amend, or delete Your information at any time by signing in to Your Account, if you have one, and visiting the account settings section that allows you to manage Your personal information. You may also contact Us to request access to, correct, or delete any personal information that You have provided to Us.

Please note, however, that We may need to retain certain information when we have a legal obligation or lawful basis to do so.

## Disclosure of Your Personal Data

### Business Transactions

If the Company is involved in a merger, acquisition or asset sale, Your Personal Data may be transferred. We will provide notice before Your Personal Data is transferred and becomes subject to a different Privacy Policy.

#### Law enforcement

Under certain circumstances, the Company may be required to disclose Your Personal Data if required to do so by law or in response to valid requests by public authorities (e.g. a court or a government agency).

#### Other legal requirements

The Company may disclose Your Personal Data in the good faith belief that such action is necessary to:

- Comply with a legal obligation

- Protect and defend the rights or property of the Company

- Prevent or investigate possible wrongdoing in connection with the Service

- Protect the personal safety of Users of the Service or the public

- Protect against legal liability


### Security of Your Personal Data

The security of Your Personal Data is important to Us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While We strive to use commercially acceptable means to protect Your Personal Data, We cannot guarantee its absolute security.

## GDPR Privacy

### Legal Basis for Processing Personal Data under GDPR

We may process Personal Data under the following conditions:

- Consent: You have given Your consent for processing Personal Data for one or more specific purposes.

- Performance of a contract: Provision of Personal Data is necessary for the performance of an agreement with You and/or for any pre-contractual obligations thereof.

- Legal obligations: Processing Personal Data is necessary for compliance with a legal obligation to which the Company is subject.

- Vital interests: Processing Personal Data is necessary in order to protect Your vital interests or of another natural person.

- Public interests: Processing Personal Data is related to a task that is carried out in the public interest or in the exercise of official authority vested in the Company.

- Legitimate interests: Processing Personal Data is necessary for the purposes of the legitimate interests pursued by the Company.


In any case, the Company will gladly help to clarify the specific legal basis that applies to the processing, and in particular whether the provision of Personal Data is a statutory or contractual requirement, or a requirement necessary to enter into a contract.

### Your Rights under the GDPR

The Company undertakes to respect the confidentiality of Your Personal Data and to guarantee You can exercise Your rights.

You have the right under this Privacy Policy, and by law if You are within the EU, to:

- Request access to Your Personal Data. The right to access, update or delete the information We have on You. Whenever made possible, you can access, update or request the deletion of Your Personal Data by emailing us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk). This also enables You to receive a copy of the Personal Data We hold about You.

- Request correction of the Personal Data that We hold about You. You have he right to have any incomplete or inaccurate information We hold about You corrected.

- Object to processing of Your Personal Data. This right exists where We are relying on a legitimate interest as the legal basis for Our processing and there is something about Your particular situation, which makes You want to object to our processing of Your personal Data on this ground.

- You also have the right to object where We are processing Your Personal Data for direct marketing purposes.

- Request erasure of Your Personal Data. You have the right to ask Us to delete or remove Personal Data when there is no good reason for Us to continue processing it.

- Request the transfer of Your Personal Data. We will provide to You, or to a third-party You have chosen, Your Personal Data in a structured, commonly used, machine-readable format. Please note that this right only applies to automated information which You initially provided consent for us to use or where We used the information to perform a contract with You.

- Withdraw Your consent. You have the right to withdraw Your consent on using your Personal Data. If You withdraw Your consent, We may not be able to provide You with access to certain specific functionalities of the Service.


### Exercising of Your GDPR Data Protection Rights

You may exercise Your rights of access, rectification, cancellation and opposition by contacting Us. Please note that we may ask You to verify Your identity before responding to such requests. If You make a request, We will try our best to respond to You as soon as possible.

You have the right to complain to a Data Protection Authority about Our collection and use of Your Personal Data. For more information, if You are in the European Economic Area (EEA), please contact Your local data protection authority in the EEA.

### Children's Privacy

Our Service does not address anyone under the age of 13. We do not knowingly collect personally identifiable information from anyone under the age of 13. If You are a parent or guardian and You are aware that Your child has provided Us with Personal Data, please contact Us. If We become aware that We have collected Personal Data from anyone under the age of 13 without verification of parental consent, We take steps to remove that information from Our servers.

If We need to rely on consent as a legal basis for processing Your information and Your country requires consent from a parent, We may require Your parent's consent before We collect and use that information.

### Links to Other Websites

Our Service may contain links to other websites that are not operated by Us. If You click on a third party link, You will be directed to that third party's site. We strongly advise You to review the Privacy Policy of every site You visit.

We have no control over and assume no responsibility for the content, privacypolicies or practices of any third party sites or services.

## Changes to this Privacy Policy

We may update Our Privacy Policy from time to time. We will notify You of any changes by posting the new Privacy Policy on this page.

We will let You know via email and/or a prominent notice on Our Service, prior to the change becoming effective and update the "Last updated" date at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

## Contact Us

If you have any questions about this Privacy Policy, You can contact us:

\\* By email: [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk)

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Cookie Policy Overview
# Cookie Policy

Last updated Jan 20, 2024

This Cookie Policy explains how "Synthesis Health", "Company," "we," "us," and "our") uses cookies and similar technologies to recognize you when you visit our website at [https://synthesishealth.co.uk](https://synthesishealth.co.uk/)("Website"). It explains what these technologies are and why we use them, as well as your rights to control our use of them.

In some cases we may use cookies to collect personal information, or that becomes personal information if we combine it with other information.

## What are cookies?

Cookies are small data files that are placed on your computer or mobile device when you visit a website. Cookies are widely used by

website owners in order to make their websites work, or to work more efficiently, as well as to provide reporting information.

Cookies set by the website owner (in this case, Synthesis Health) are called "first-party cookies." Cookies set by parties other than the website owner are called "third-party cookies." Third-party cookies enable third-party features or functionality to be provided on or through the website (e.g., advertising, interactive content, and analytics).

The parties that set these third-party cookies can recognize your computer both when it visits the website in question and also when it visits certain other websites.

### Why do we use cookies?

We use first- and third-party cookies for several reasons. Some cookies are required for technical reasons in order for our Website to operate, and we refer to these as "essential" or "strictly necessary" cookies. Other cookies also enable us to track and target the interests of our users to enhance the experience on our Online Properties. Third parties serve cookies through our Website for advertising, analytics, and other purposes. This is described in more detail below.

### How can I control cookies?

You have the right to decide whether to accept or reject cookies.

You can exercise your cookie rights by setting your preferences in the Cookie Consent Manager. The Cookie Consent Manager allows you to select which categories of cookies you accept or reject. Essential cookies cannot be rejected as they are strictly necessary to provide you with services.

The Cookie Consent Manager can be found in the notification banner and on our website. If you choose to reject cookies, you may still use our website though your access to some functionality and areas of our website may be restricted. You may also set or amend your web browser controls to accept or refuse cookies.

The specific types of first- and third-party cookies served through our Website and the purposes they perform are described in the table below (please note that the specific cookies served may vary depending on the specific Online Properties you visit):

### Analytics and customization cookies:

These cookies collect information that is used either in aggregate form to help us understand how our Website is being used or how effective our marketing campaigns are, or to help us customize our Website for you.

* * *

Name: **_ga_** **#**

Purpose: **Used to distinguish individual users by means of designation of a randomly generated number as client identifier, which allows calculation of visits and sessions**

Provider: . [synthesishealth.co.uk](http://synthesishealth.co.uk/)

Service: **Google Analytics**

[View Service Privacy Policy](https://policies.google.com/privacy)

Type: **http\_cookie**

Expires in: **1 year 1 month 4 days**

* * *

Name: **_ga_**

Purpose: **Records a particular ID used to come up with data about website usage by the user**

Provider: **.** [**synthesishealth.co.uk**](http://synthesishealth.co.uk/)

Service: **Google Analytics**

[View Service Privacy Policy](https://policies.google.com/privacy)

Type: **http\_cookie**

Expires in: **1 year 1 month 4 days**

* * *

### How can I control cookies on my browser?

As the means by which you can refuse cookies through your web browser controls vary from browser to browser, you should visit your browser's help menu for more information. The following is information about how to manage cookies on the most popular browsers:

- Chrome

- Internet Explorer

- Firefox

- Safari

- Edge

- Opera


In addition, most advertising networks offer you a way to opt out of targeted advertising. If you would like to find out more information, please visit:

- Digital Advertising Alliance

- Digital Advertising Alliance of Canada

- European Interactive Digital Advertising Alliance


#### What about other tracking technologies, like web beacons?

Cookies are not the only way to recognize or track visitors to a website. We may use other, similar technologies from time to time, like web beacons (sometimes called "tracking pixels" or "clear gifs"). These are tiny graphics files that contain a unique identifier that enables us to recognize when someone has visited our Website or opened an email including them. This allows us, for example, to monitor the traffic patterns of users from one page within a website to another, to deliver or communicate with cookies, to understand whether you have come to the website from an online advertisement displayed on a third-party website, to improve site performance, and to measure the success of email marketing campaigns. In many instances, these technologies are reliant on cookies to function properly, and so declining cookies will impair their functioning.

#### Do you use Flash cookies or Local Shared Objects?

Websites may also use so-called "Flash Cookies" (also known as Local Shared Objects or "LSOs") to, among other things, collect and store information about your use of our services, fraud prevention, and for other site operations.

If you do not want Flash Cookies stored on your computer, you can adjust the settings of your Flash player to block Flash Cookies storage using the tools contained in the Website Storage Settings Panel . You can also control Flash Cookies by going to the Global Storage Settings Panel and following the instructions (which may include instructions that explain, for example, how to delete existing Flash Cookies (referred to "information" on the Macromedia site), how to prevent Flash LSOs from being placed on your computer without your being asked, and (for Flash Player 8 and later) how to block Flash Cookies that are not being delivered by the operator of the page you are on at the time).

Please note that setting the Flash Player to restrict or limit acceptance of Flash Cookies may reduce or impede the functionality of some Flash applications, including, potentially, Flash applications used in connection with our services or online content.

#### Do you serve targeted advertising?

Third parties may serve cookies on your computer or mobile device to serve advertising through our Website. These companies may use information about your visits to this and other websites in order to provide relevant advertisements about goods and services that you may be interested in. They may also employ technology that is used to measure the effectiveness of advertisements. They can accomplish this by using cookies or web beacons to collect information about your visits to this and other sites in order to provide relevant advertisements about goods and services of potential interest to you.

The information collected through this process does not enable us or them to identify your name, contact details, or other details that directly identify you unless you choose to provide these.

#### How often will you update this Cookie Policy?

We may update this Cookie Policy from time to time in order to reflect, for example, changes to the cookies we use or for other operational, legal, or regulatory reasons. Please therefore revisit this Cookie Policy regularly to stay informed about our use of cookies and related technologies.

The date at the top of this Cookie Policy indicates when it was last updated.

#### Where can I get further information?

If you have any questions about our use of cookies or other technologies, please email us at [info@synthesishealth.co.uk](mailto:info@synthesishealth.co.uk) or by post to:

Synthesis Health

SD 340-28, 03 The Offices 3, One Central

Dubai World Trade Centre

Dubai

United Arab Emirates

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient Engagement Strategies
# Patient Engagement & Patient Centricity

We're passionate about bridging the gap between pharmaceutical companies and stakeholders by promoting productive partnerships that can lead to more effective and patient-centric approaches.

These collaborations offer the commitment and perseverance to drive true systemic change, but this is only achievable when their key learnings are circulated throughout the industry.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27512%27%20height=%27768%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F640x960%2F747f051be3%2Flaptop.jpg&w=1080&q=90)

## Patient and stakeholder partnerships

As recent evolutions in the healthcare environment have demanded a greater focus on patient centricity and engagement, publishing the outputs of stakeholder partnerships creates meaningful value for patients, the industry, the healthcare system and society as a whole by:

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%272666.6666666666665%27%20height=%274000%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F4000x6000%2F6c518d3e93%2Fresearcher.jpg&w=3840&q=90)

1

### Amplifying patient voices

Publications ensure patient contributions are heard, acknowledged, and hopefully later integrated into research and development processes.

1

### Amplifying patient voices

Publications ensure patient contributions are heard, acknowledged, and hopefully later integrated into research and development processes.

2

### Improving health outcomes

Insights can be accessed and incorporated into decision-making processes across different healthcare settings.

2

### Improving health outcomes

Insights can be accessed and incorporated into decision-making processes across different healthcare settings.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%272376.6666666666665%27%20height=%273564.6666666666665%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3565x5347%2F5792da5200%2Fdecision.jpg&w=3840&q=90)

3

### Disseminating knowledge

Industry stakeholders are empowered to make more informed decisions and influence healthcare practices that better meet patient needs.

3

### Disseminating knowledge

Industry stakeholders are empowered to make more informed decisions and influence healthcare practices that better meet patient needs.

4

### Driving greater impact

Providing credible evidence to policymakers and regulatory agencies is integral to driving systemic change and shaping policies that align with patient interests.

4

### Driving greater impact

Providing credible evidence to policymakers and regulatory agencies is integral to driving systemic change and shaping policies that align with patient interests.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%274224%27%20height=%276336%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F6336x9504%2F7a76d04bb7%2Fteam.jpg&w=3840&q=90)

5

### Encouraging innovation and collaboration

Broadcasting patient engagement activities encourages other pharma companies and stakeholders to work together to drive transformation across different settings.

5

### Encouraging innovation and collaboration

Broadcasting patient engagement activities encourages other pharma companies and stakeholders to work together to drive transformation across different settings.

6

### Enhancing corporate reputation

Showcasing a commitment to stakeholders elevates a company's reputation as one that values patient engagement and actively supports patient advocacy.

6

### Enhancing corporate reputation

Showcasing a commitment to stakeholders elevates a company's reputation as one that values patient engagement and actively supports patient advocacy.

## Work with us

[Full Project Support](https://synthesishealth.co.uk/work-with-us)

From providing strategic input to maximise the quality of stakeholder engagement data and insights to specialist medical writing support in developing impactful publications, we offer end-to-end services that disseminate project outputs to benefit patients and the wider industry.

[Full Project Support](https://synthesishealth.co.uk/work-with-us)

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Synthesis Health Blog
# An act of Synthesis

Our team consists of incredibly talented writers who occasionally like to share their thinking and expertise. Find out more in our articles below.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%271626%27%20height=%271476%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1626x1476%2Febf45a3284%2Fink-pot.png&w=3840&q=90)

1 May 2025

## Improving direct patient access to clinical trials

Discover how the healthcare industry can empower patients with the resources and knowledge to access relevant clinical trials and make informed decisions about participation.

[Read the article](https://synthesishealth.co.uk/blog/improving-direct-patient-access-to-clinical-trials)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F6720x4480%2Fdbcd423084%2Fclinical-trial-2.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F6720x4480%2Fdbcd423084%2Fclinical-trial-2.jpg&w=1080&q=90)

1 May 2025

## Educating healthcare professionals for patient-centred care

Today’s medical education ensures practitioners deliver high-quality, evidence-based care. But are healthcare professionals equipped with valuable content and resources to foster collaborative patient-focused discussions driven by trust and mutual respect?

[Read the article](https://synthesishealth.co.uk/blog/educating-healthcare-professionals-for-patient-centred-care)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3937x2625%2Fd9c1837f55%2Fmedical-school.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3937x2625%2Fd9c1837f55%2Fmedical-school.jpg&w=1080&q=90)

13 April 2025

## Behind the psychology of patient engagement: How to unlock motivators and overcome barriers

Patient engagement is transforming healthcare, but what drives individuals to take an active role in their care?

[Read the article](https://synthesishealth.co.uk/blog/behind-the-psychology-of-patient-engagement)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3999x2666%2F971ee6fae8%2Funlock.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3999x2666%2F971ee6fae8%2Funlock.jpg&w=1080&q=90)

11 March 2025

## The power of gap analyses in driving medical discovery

Despite the rapid advancements in healthcare research, critical gaps in knowledge remain—especially in rare diseases. How can we identify and address these gaps to drive meaningful progress?

[Read the article](https://synthesishealth.co.uk/blog/the-power-of-gap-analyses-in-driving-medical-discovery)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1626x1080%2Ff1d013225d%2Fgap-analysis.png&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1626x1080%2Ff1d013225d%2Fgap-analysis.png&w=1080&q=90)

18 February 2025

## Understanding patient experiences in clinical trials: Should exit interviews be considered essential?

How do clinical trial exit interviews shape patient-centric research, and should they be standard practice?

[Read the article](https://synthesishealth.co.uk/blog/should-exit-interviews-be-essential-in-clinical-trials)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F4000x2667%2Fea2f276e41%2Fexit-interview.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F4000x2667%2Fea2f276e41%2Fexit-interview.jpg&w=1080&q=90)

5 December 2024

## Transforming the rare disease landscape: The essential role of patient advocacy groups and pharma

Discover how patient advocacy groups (PAGs) are transforming rare disease research by bridging the gap between patients, caregivers, and the pharmaceutical industry. Learn more about their mission to improve healthcare outcomes and how the pharmaceutical industry can collaborate to develop life-changing therapies for those most in need.

[Read the article](https://synthesishealth.co.uk/blog/transforming-the-rare-disease-landscape)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5040x3360%2F0d406a25ef%2Fcommunity-hands.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5040x3360%2F0d406a25ef%2Fcommunity-hands.jpg&w=1080&q=90)

7 November 2024

## Patient insight-led drug development: Ensuring patients are at the centre of clinical trial design

Discover how patient insight-led drug development ensures patients are at the heart of clinical trial design. Learn how integrating diverse patient feedback can enhance trial accessibility, improve outcomes, and drive true patient-centricity in healthcare.

[Read the article](https://synthesishealth.co.uk/blog/patient-insight-led-drug-development)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F6240x4160%2F998ee3d68f%2Fpatient-medicine.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F6240x4160%2F998ee3d68f%2Fpatient-medicine.jpg&w=1080&q=90)

18 February 2025

## Patient-Reported Outcomes (PROs) — what they are and why they matter

Patient-reported outcomes (PROs) are crucial in modern healthcare, providing direct insights from patients about their health status, which helps align medical research and development with patient needs.

[Read the article](https://synthesishealth.co.uk/blog/patient-reported-outcomes-what-they-are-and-why-they-matter)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3707x3858%2F50fbd9a8fd%2Fpatient-reported-outcomes.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3707x3858%2F50fbd9a8fd%2Fpatient-reported-outcomes.jpg&w=1080&q=90)

18 September 2024

## Building health equity: How can we mitigate barriers to diverse clinical trial participation?

As the medical industry strives to promote health equity, addressing the lack of diversity in clinical trials has become a key priority. Despite progress, many groups remain underrepresented. This underrepresentation affects the efficacy and safety of treatments for these patients.

[Read the article](https://synthesishealth.co.uk/blog/building-health-equity-how-can-we-mitigate-barriers-to-diverse-clinical-trial-participation)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3888x2591%2F02bb65c09a%2Fdiverse-patient.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F3888x2591%2F02bb65c09a%2Fdiverse-patient.jpg&w=1080&q=90)

6 August 2024

## Empowering voices: The rise of patient-authored publications in healthcare

With a notable rise in patient contributions in medical journals, discover the benefits of incorporating patient perspectives into scientific publications and how this approach shapes a more inclusive and effective healthcare landscape.

[Read the article](https://synthesishealth.co.uk/blog/empowering-voices-the-rise-of-patient-authored-publications-in-healthcare)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F2996x2104%2Febaee5fde6%2Fstack-paper.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F2996x2104%2Febaee5fde6%2Fstack-paper.jpg&w=1080&q=90)

11 July 2024

## Embracing patient perspectives: A catalyst for advancing healthcare outcomes

Embracing patient perspectives revolutionises healthcare by fostering patient engagement, tailoring treatment solutions, and innovating care.

[Read the article](https://synthesishealth.co.uk/blog/embracing-patient-perspectives-a-catalyst-for-advancing-healthcare-outcomes)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F8182x5455%2F6133a05f50%2Flistening-patients.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F8182x5455%2F6133a05f50%2Flistening-patients.jpg&w=1080&q=90)

4 June 2024

## Health literacy: The gatekeeper for patient health outcomes

Discover how health literacy acts as a critical gateway to patient empowerment and improved healthcare outcomes.

[Read the article](https://synthesishealth.co.uk/blog/health-literacy-the-gatekeeper-for-patient-health-outcomes)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5760x3840%2F4490021a88%2Fconfused-patient.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5760x3840%2F4490021a88%2Fconfused-patient.jpg&w=1080&q=90)

30 April 2024

## What motivates patients and caregivers to engage in health research?

Explore the multifaceted motivations behind patient involvement and how it shapes the future of health research. Dive into the heart of patient-centric innovation and learn how Synthesis is leading the way in fostering meaningful connections between patients and the healthcare industry.

[Read the article](https://synthesishealth.co.uk/blog/what-motivates-patients-and-caregivers-to-engage-in-health-research)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F6000x4000%2F76232c7956%2Fpatient-discussion.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F6000x4000%2F76232c7956%2Fpatient-discussion.jpg&w=1080&q=90)

4 April 2024

## Identifying representative patients in healthcare: Why – and how – you should communicate a diverse patient voice

Learn how embracing diverse patient perspectives is revolutionising research, enhancing equality, and tailoring healthcare outcomes to meet the unique needs of every individual.

[Read the article](https://synthesishealth.co.uk/blog/identifying-representative-patients-in-healthcare)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5760x3840%2F7fb1fdfd39%2Fdiverse-engagement.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5760x3840%2F7fb1fdfd39%2Fdiverse-engagement.jpg&w=1080&q=90)

3 April 2024

## The power of patient partnerships: Why you should publish patient engagement outputs

Publishing the insights from patient partnership collaborations is a crucial step for pharma companies to revolutionise the pharmaceutical industry's approach to patient engagement.

[Read the article](https://synthesishealth.co.uk/blog/the-power-of-patient-partnerships)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F4272x2848%2F8bb6437fed%2Fsharing-knowledge.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F4272x2848%2F8bb6437fed%2Fsharing-knowledge.jpg&w=1080&q=90)

3 April 2024

## Unlocking the power of co-creation: Patient communities and pharma

Patient engagement is no longer a ‘nice-to-have’ but a fundamental ‘must-do’ for pharma in an ever-increasing patient-focused future.

[Read the article](https://synthesishealth.co.uk/blog/unlocking-the-power-of-co-creation-patient-communities-and-pharma)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5472x3648%2F08b56e974d%2Fpatient-pharma-partner.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5472x3648%2F08b56e974d%2Fpatient-pharma-partner.jpg&w=1080&q=90)

4 April 2024

## 6 ways your medical manuscript could benefit from medical writing support

As specialists in writing for the medical field, medical writers are perfectly placed to help overcome the publishing challenges facing clinicians and scientists.

[Read the article](https://synthesishealth.co.uk/blog/6-ways-your-medical-manuscript-could-benefit-from-medical-writing-support)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![Analysing data and results of a medical scan](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F8839x5893%2F1b1f1f975f%2Fdata-analytics.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![Analysing data and results of a medical scan](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F8839x5893%2F1b1f1f975f%2Fdata-analytics.jpg&w=1080&q=90)

4 April 2024

## 8 reasons why journals may reject your manuscripts

Why do so many manuscripts fail to make it to the peer review process, and how can you ensure your manuscripts stand the best possible chances of successful submission?

[Read the article](https://synthesishealth.co.uk/blog/8-reasons-why-your-manuscripts-aren-t-being-accepted-by-journals)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27400%27%20height=%27500%27/%3e)![Writer with hands in head in front of a laptop](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5184x3456%2F979c05049b%2Ffrustrated-author.jpg&w=828&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27500%27%20height=%27300%27/%3e)![Writer with hands in head in front of a laptop](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F5184x3456%2F979c05049b%2Ffrustrated-author.jpg&w=1080&q=90)

![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1512x688%2F2d52b4bae7%2Fbuildings-rising.png&w=3840&q=90)

## Develop publication-ready content today

[Book a call](https://calendly.com/synthesis-sam/synthesis-call)

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Healthcare Communication Experts
# Our work

With over 25 years of healthcare communications experience with exceptional clients, you can rely on us to provide meticulous editorial support across all stages of medical manuscript development and publication.

- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27100%27%20height=%27100%27/%3e)![Bayer logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F200x200%2F2e1c56de7e%2Fbayer.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27208%27%20height=%27100%27/%3e)![Pfizer logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F416x200%2F8d06a6d7ed%2Fpfizer.png&w=640&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27127%27%20height=%2734%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F254x68%2F794fc5f9ff%2Fgilead-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27107%27%20height=%27100%27/%3e)![GSK logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F214x200%2Fc19da5ebd7%2Fgsk.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27128%27%20height=%27100%27/%3e)![NHS Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F256x200%2Fc87e0708d9%2Fnhs.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27100%27%20height=%2750%27/%3e)![Thalidomide Trust Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F200x100%2F25c0123667%2Fthalidomide-logo-black.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27251%27%20height=%2746.5%27/%3e)![Galderma Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F502x93%2F5dcfc429b5%2Fgalderma-black.png&w=640&q=90)

## What  people say  about us

_With Synthesis, we know we have trusted partners who drive and maintain the same high standards we pride ourselves on, in terms of both content development and author management. What’s more is that we can rely on their unparalleled expertise from conception to final manuscript execution, to be true strategic sparring partners that deliver added value at every step of the publication process."_

> Jess Pacey, CEO, **_67Health_**

_"I have worked with the lead writer of the Synthesis team for over 20 years as my medical writer of choice. Whether it is an abstract, a first draft manuscript or a case study, and whatever the therapeutic area, the first draft is always beautifully written and requires very few edits. The expansion of the team to include additional strategic input and writing skills has added to the quality of their work. If only all medical writers could be like Synthesis Health.”_

> Alexa Forbes, Founder, **_Consulting Ltd_**

_The value that Synthesis added to our project was inestimable. Their content development expertise ensured we were able to achieve a truly excellent manuscript, while their skill at managing the process and the authors ensured a well-organised and effective approach. We were completely confident in their advice and guidance and felt that at all times, they understood and remained focused on the needs and purpose of the organisation._

> Katy Sagoe, Director of Health and Wellbeing, **_The Thalidomide Trust_**

_"The lead medical writer at Synthesis and I have partnered on many different writing projects over the last 10 years, including abstracts, posters, and manuscripts. In addition to a deep knowledge of the disease area, indispensable strategic advice, and a true understanding of the message we want to convey, her writing always contains real heart. This is invaluable when writing in rare diseases and is key to the success of our projects."_

> Deborah Corcoran, Director, **Kernel Communications and Advocacy**

## Our partners

We have been fortunate to work with many healthcare communication agencies in our time. We have formed close partnerships with aligned agencies in instances where there are mutually beneficial opportunities to provide wider services to clients.

Interested in partnering with us?

[Partner with us](mailto:info@synthesishealth.co.uk?subject=Partnership%20enquiry&body=Hello%0A%0AWe%20are%20interested%20in%20potentially%20partnering%20with%20Synthesis,%20here%20is%20a%20little%20information%20us%20to%20introduce%20ourselves....)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27453.33333333333337%27%20height=%27166.66666666666669%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F544x200%2Fc3d691f42c%2F67-health-logo.png&w=1080&q=90)

## Want to join the team?

At Synthesis, you’re not going to find a token ping-pong table, free kombucha and a floor of uncomfortable bean bags. We don’t believe in trendy, millennial perks. But, you can expect remote working by default, 28 days of annual leave and a four-day work week. For more information about career opportunities, please send us an email and your CV using the link below.

[Apply to join the team](mailto:info@synthesishealth.co.uk?subject=Apply%20to%20Synthesis&body=Hi%20%0A%0A%20I%20am%20interesed%20in%20learning%20more%20about%20working%20with%20Synthesis:%20%0A%0A-%20My%20name%20is:%20%0A%0A-%20I've%20attached%20my%20CV%20below.%20%0A%0A-%20Here%20is%20a%20short%20summary%20of%20me:%20%0A%0A-%20I%20am%20interested%20in%20working%20with%20Synthesis%20because...)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27606%27%20height=%27668%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F606x668%2F63b5243363%2Fcomputer-on-desk.png&w=1920&q=90)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1512x688%2F2d52b4bae7%2Fbuildings-rising.png&w=3840&q=90)

## Develop pulication-readycontent today

[Book a call](https://calendly.com/synthesis-sam/synthesis-call)

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Work with Synthesis
# Concept to creation.  Start tomorrow.

[Book in a call](https://calendly.com/synthesis-sam/synthesis-call) [Drop us an email](mailto:info@synthesishealth.co.uk?subject=Working%20with%20Synthesis%20Enquiry)

To learn more about how Synthesis can help you, please get in touch.

## What  people say  about us

_"With Synthesis, we know we have trusted partners who drive and maintain the same high standards we pride ourselves on, in terms of both content development and author management. What’s more is that we can rely on their unparalleled expertise from conception to final manuscript execution, to be true strategic sparring partners that deliver added value at every step of the publication process."_

> Jess Pacey, CEO, **_67Health_**

_"I have worked with the lead writer of the Synthesis team for over 20 years as my medical writer of choice. Whether it is an abstract, a first draft manuscript or a case study, and whatever the therapeutic area, the first draft is always beautifully written and requires very few edits. The expansion of the team to include additional strategic input and writing skills has added to the quality of their work. If only all medical writers could be like Synthesis Health.”_

> Alexa Forbes, Founder, **Alexa Forbes** **_Consulting Ltd_**

_"The value that Synthesis added to our project was inestimable. Their content development expertise ensured we were able to achieve a truly excellent manuscript, while their skill at managing the process and the authors ensured a well-organised and effective approach. We were completely confident in their advice and guidance and felt that at all times, they understood and remained focused on the needs and purpose of the organisation."_

> Katy Sagoe, Director of Health and Wellbeing, **_The Thalidomide Trust_**

_"The lead medical writer at Synthesis and I have partnered on many different writing projects over the last 10 years, including abstracts, posters, and manuscripts. In addition to a deep knowledge of the disease area, indispensable strategic advice, and a true understanding of the message we want to convey, her writing always contains real heart. This is invaluable when writing in rare diseases and is key to the success of our projects."_

> Deborah Corcoran, Director, **_Kernel Communications and Advocacy_**

## Our partners

We have been fortunate to work with many healthcare communication agencies in our time. We have formed close partnerships with aligned agencies in instances where there are mutually beneficial opportunities to provide wider services to clients.

Interested in partnering with us?

[Partner with us](mailto:info@synthesishealth.co.uk?subject=Partnership%20enquiry&body=Hello%0A%0AWe%20are%20interested%20in%20potentially%20partnering%20with%20Synthesis,%20here%20is%20a%20little%20information%20us%20to%20introduce%20ourselves....)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27453.33333333333337%27%20height=%27166.66666666666669%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F544x200%2Fc3d691f42c%2F67-health-logo.png&w=1080&q=90)

## Want to join the team?

At Synthesis, you’re not going to find a token ping-pong table, free kombucha, or a floor of uncomfortable bean bags. We don’t believe in trendy, millennial perks. But, you can expect remote working by default, 28 days of annual leave and a 4.5 day work week. For more information about career opportunities, please send us an email and your CV using the link below.

[Apply to join the team](mailto:info@synthesishealth.co.uk?subject=Apply%20to%20Synthesis&body=Hi%20%0A%0A%20I%20am%20interesed%20in%20learning%20more%20about%20working%20with%20Synthesis:%20%0A%0A-%20My%20name%20is:%20%0A%0A-%20I've%20attached%20my%20CV%20below.%20%0A%0A-%20Here%20is%20a%20short%20summary%20of%20me:%20%0A%0A-%20I%20am%20interested%20in%20working%20with%20Synthesis%20because...)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27606%27%20height=%27668%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F606x668%2F63b5243363%2Fcomputer-on-desk.png&w=1920&q=90)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1512x688%2F2d52b4bae7%2Fbuildings-rising.png&w=3840&q=90)

## Write the future of healthcare today

[Book a call](https://calendly.com/synthesis-sam/synthesis-call)

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Patient Advocacy Solutions
# Your communications powerhouse

- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27100%27%20height=%27100%27/%3e)![Bayer logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F200x200%2F2e1c56de7e%2Fbayer.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27208%27%20height=%27100%27/%3e)![Pfizer logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F416x200%2F8d06a6d7ed%2Fpfizer.png&w=640&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27127%27%20height=%2734%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F254x68%2F794fc5f9ff%2Fgilead-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27107%27%20height=%27100%27/%3e)![GSK logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F214x200%2Fc19da5ebd7%2Fgsk.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27128%27%20height=%27100%27/%3e)![NHS Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F256x200%2Fc87e0708d9%2Fnhs.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27100%27%20height=%2750%27/%3e)![Thalidomide Trust Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F200x100%2F25c0123667%2Fthalidomide-logo-black.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27251%27%20height=%2746.5%27/%3e)![Galderma Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F502x93%2F5dcfc429b5%2Fgalderma-black.png&w=640&q=90)

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27374.6666666666667%27%20height=%27506.6666666666667%27/%3e)![ ](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F562x760%2F500d9b7e38%2Fhandshake.png&w=750&q=90)

### Your partner

We work with our clients to create considered, personalised solutions from evidence-based patient insights. Through our patient engagement partnerships, we strive to deliver better health outcomes for all.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27425.3333333333333%27%20height=%27600%27/%3e)![ ](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F638x900%2Fcc22d71966%2Fcrossed-legs.png&w=1080&q=90)

### Specialists

Our team has over 25 years of experience delivering communication solutions that raise the patient voice across the entire drug development lifecycle.

### Experience

Using our experience in medical communications and education, we aim to develop groundbreaking and influential solutions rooted in a deep understanding of patient needs and insights to improve the lives of patients and their caregivers.

## Synthesis was born from a need

Synthesis is dedicated to championing patient advocacy through specialised medical writing and communication strategies that portray patients' experiences of illnesses.

We work with pharma companies to amplify the voices of patients through various engagement initiatives such as advisory boards, social listening programs, or surveys. These platforms are instrumental in highlighting the often-overlooked needs and valuable perspectives of patients.

### 25 years + experience

Through our expertise in medical writing, we can help you:

- Produce high-quality, scientifically accurate documents with clear, reader-friendly language

- Convey key messages coherently and concisely

- Minimise content review cycles by assuring that all relevant guidelines and style formats are followed from the very beginning

- Adhere to guidelines and regulations governing the pharmaceutical industry

- Translate complex scientific data into clear, concise, and coherent content that can be easily understood by healthcare professionals and patients.

- Ensure accuracy, clarity and quality of deliverables through rigorous quality control processes

- Offer strategic input to maximise the impact of patient engagement activities


![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1512x688%2F2d52b4bae7%2Fbuildings-rising.png&w=3840&q=90)

## Write the future ofhealthcare today

[Book a call](https://calendly.com/synthesis-sam/synthesis-call)

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.

Okay

## Manuscript Support Services
# Manuscript Support

Synthesis is a specialist medical communications agency that provides meticulous editorial support across all stages of medical manuscript development and submission.

Our ability to understand different therapeutic areas, identify relevant publication concepts, and plan and deliver high-quality scientific writing means that we can partner with you to enhance the strategic impact and value of your content.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27427.2%27%20height=%27640.8%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F534x801%2Ff4084068c3%2Fdoctore-with-needle.png&w=1080&q=90)

- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27172.5%27%20height=%2730.5%27/%3e)![European Journal of Radiology Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F345x61%2F0f07637905%2Fej-radiology-logo.png&w=384&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2789%27%20height=%2756%27/%3e)![European Society of Cardiology Journal](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F178x112%2Fce90803b26%2Fesc-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2778%27%20height=%2743%27/%3e)![Allergy & Asthma Proceedings](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F156x86%2F386ab6e1af%2Fallery-asthma-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27173.5%27%20height=%2730.5%27/%3e)![Musculoskeletal Care Journal Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F347x61%2F69a1079c12%2Fmusculoskeletal-logo.png&w=384&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27167%27%20height=%2743%27/%3e)![Dermatologic Surgery Journal](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F334x86%2F919f8b002c%2Fdermatologic-surgery.png&w=384&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2786.5%27%20height=%2734%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F173x68%2F6e7dd26961%2Faogs-logo.png&w=256&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2744%27%20height=%2743%27/%3e)![Orphanet Journal of Rare Diseases Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F88x86%2F8570e41e86%2Forjd-logo.png&w=96&q=90)
- ![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27101%27%20height=%2737%27/%3e)![ISH Logo](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F202x74%2Fd423c91c17%2Fish-logo.png&w=256&q=90)

## Our Manuscript Development Process

Your trusted partner throughout the entire life cycle of your manuscript

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27436%27%20height=%27805.3333333333334%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F654x1208%2F8ba6df55eb%2Fmen-working.png&w=1080&q=90)

1

### Journal Selection

We research potential journals to match your content to the appropriate readership.

1

### Journal Selection

We research potential journals to match your content to the appropriate readership.

2

### Draft Development

From initial outline to final draft, our team works with your authors to produce high-quality, appropriate content for journal submission.

2

### Draft Development

From initial outline to final draft, our team works with your authors to produce high-quality, appropriate content for journal submission.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27482.6666666666667%27%20height=%27878.6666666666666%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F724x1318%2Fa4397fb857%2Fwoman-working.png&w=1080&q=90)

3

### Journal Formatting

Our team ensures that all material is formatted according to the target journal guidelines.

3

### Journal Formatting

Our team ensures that all material is formatted according to the target journal guidelines.

4

### Quality Control

Our team ensures that content, style and format are high-quality at every step.

4

### Quality Control

Our team ensures that content, style and format are high-quality at every step.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27412.6666666666667%27%20height=%27832%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F619x1248%2F42657bd3d4%2Fdoctor-analysing.png&w=828&q=90)

5

### Citations

We ensure accurate and appropriate referencing to place your research methodology, findings and implications into relevant context.

5

### Citations

We ensure accurate and appropriate referencing to place your research methodology, findings and implications into relevant context.

6

### Journal Submission

We assist with journal submission guidelines and processes where needed and work with you to agree and implement post-review changes and detailed responses to reviewers for re-submission.

6

### Journal Submission

We assist with journal submission guidelines and processes where needed and work with you to agree and implement post-review changes and detailed responses to reviewers for re-submission.

## Beyond manuscripts

As well as diverse domain expertise and medical writing skills, we believe that an effective publications plan requires expertise in strategic planning, project management and marketing. Talk to us today to find out more about how we can support you in the preparation of congress submissions and publications planning.

[Book a call](https://calendly.com/synthesis-sam/synthesis-call)

## Benefit from a publications plan

Whether your pharmaceutical product is an early-stage asset meriting a late-breaking abstract or a mature product with an abundant data pipeline, a well-developed and executed publications plan is fundamental to a product’s entry, uptake and growth in clinical practice.

* * *

#### Achieve concise and coherent content

By combining diverse domain knowledge and exceptional writing skills, we integrate the expertise of your researchers, publications team and authors to achieve concise and coherent manuscript content and enhance the potential for journal acceptance.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27826.6666666666666%27%20height=%27593.3333333333334%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1240x890%2F637c19371c%2Fmeeting-room.png&w=1920&q=90)

#### Reduce content development timelines

With our planning support, you can reduce content development timelines, improve the chances of congress and journal submission acceptance, and support the dissemination of product and disease awareness.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27826.6666666666666%27%20height=%27533.3333333333334%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1240x800%2Fde40747573%2Fcoffee-laptop-tablet.png&w=1920&q=90)

#### Reach the right audience at the right time

From doctors and nurses to pharmacists, payers and carers, we can help you ensure they have all the information they need to make optimal decisions for patients.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27826.6666666666666%27%20height=%27533.3333333333334%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1240x800%2Fc378271116%2Fsolar-panels.png&w=1920&q=90)

#### Reinforce your scientific integrity and reputation

We can help you develop high-quality, accurate and compliant submissions that promote and reinforce your scientific integrity and reputation.

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27826.6666666666666%27%20height=%27533.3333333333334%27/%3e)![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1240x800%2F362fe42ebd%2Ffemale-lecturer.png&w=1920&q=90)

[Start your publication plan](https://calendly.com/synthesis-sam/synthesis-call)

![](https://synthesishealth.co.uk/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F166410%2F1512x688%2F2d52b4bae7%2Fbuildings-rising.png&w=3840&q=90)

## Develop publication-ready content today

[Book a call](https://calendly.com/synthesis-sam/synthesis-call)

This website uses only necessary cookies to enhance the user experience. View our [Privacy Policy](https://synthesishealth.co.uk/privacy-policy) and our [Cookie Policy](https://synthesishealth.co.uk/cookie-policy) for more information.